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Summary
Tickborne rickettsial diseases (TBRD) continue to cause severe illness and death in otherwise healthy adults and children,
despite the availability of low cost, effective antimicrobial therapy. The greatest challenge to clinicians is the difficult diagnos-
tic dilemma posed by these infections early in their clinical course, when antibiotic therapy is most effective. Early signs and
symptoms of these illnesses are notoriously nonspecific or mimic benign viral illnesses, making diagnosis difficult. In October
2004, CDC’s Viral and Rickettsial Zoonoses Branch, in consultation with 11 clinical and academic specialists of Rocky
Mountain spotted fever, human granulocytotropic anaplasmosis, and human monocytotropic ehrlichiosis, developed guide-
lines to address the need for a consolidated source for the diagnosis and management of TBRD. The preparers focused on the
practical aspects of epidemiology, clinical assessment, treatment, and laboratory diagnosis of TBRD. This report will assist
clinicians and other health-care and public health professionals to 1) recognize epidemiologic features and clinical manifes-
tations of TBRD, 2) develop a differential diagnosis that includes and ranks TBRD, 3) understand that the recommenda-
tions for doxycycline are the treatment of choice for both adults and children, 4) understand that early empiric antibiotic
therapy can prevent severe morbidity and death, and 5) report suspect or confirmed cases of TBRD to local public health
authorities to assist them with control measures and public health education efforts.
The reported incidence of these diseases has increased dur-
ing the previous decade. Despite the availability of low-
cost and effective antibiotic therapy, which may be used
empirically for suspected cases, TBRD continue to cause
severe illness and death in otherwise healthy adults and
children. The greatest challenge to clinicians is diagnosing
these infections early in their clinical course, when antibi-
otic therapy is most effective (2,3). The majority of
patients with TBRD seek medical care within 2–4 days of
onset of illness (4–7). In general, these patients are first
evaluated by family practitioners, pediatricians, internists,
emergency department (ED) physicians, or physician
extenders. Early signs and symptoms of these illnesses are
notoriously nonspecific, or they might mimic benign viral
illnesses, making diagnosis difficult. For example, even in
areas where awareness of RMSF is high, approximately
60%–75% of patients with this TBRD receive an alternate
Introduction
Tickborne rickettsial diseases (TBRD) are clinically simi-
lar, yet epidemiologically and etiologically distinct illnesses.
In the United States, these diseases include 1) Rocky Moun-
tain spotted fever (RMSF), 2) human monocytotropic (or
monocytic) ehrlichiosis (HME), 3) human granulocytotropic
(or granulocytic) anaplasmosis (HGA, formerly known as
human granulocytotropic ehrlichiosis or HGE) (1), 4)
Ehrlichia ewingii infection, and 5) other emerging TBRD.
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diagnosis on their first visit for medical care (8,9). More-
over, the earlier patients seek care in the course of their
illness, the more likely an alternate diagnosis will be made
(4). The lack of a specific initial syndrome, however, does
not imply that the course of these diseases will be benign.
In October 2004, to address the need for a consolidated
resource for the diagnosis and management of TBRD,
CDC’s Viral and Rickettsial Zoonoses Branch collaborated
with 11 clinical and academic specialists of RMSF, HGA,
and HME. These external contributors were invited by CDC
subject matter specialists to participate among clinicians
and researchers in the field of TBRD, based on direct work-
ing interactions related to case consultation and recognized
expertise from peer-reviewed publications. In December
2004, the framework of this report was developed by CDC’s
Viral and Rickettsial Zoonoses Branch, based on a sum-
mary of the peer-reviewed published reports on the epide-
miology and clinical aspects of TBRD. External contributors
further developed recommendations for the diagnosis and
treatment of TBRD based on their clinical research and
experience. All work group collaborators reviewed and pro-
vided input and approved the final content of this report.
The primary goal of this report is to provide primary
care physicians and physician extenders with practical
information to assist with the diagnosis and care of
patients with TBRD. This report provides a framework for
recognizing suggestive symptoms, considering likely alter-
native diagnoses, eliciting relevant history, requesting
appropriate diagnostic tests, and initiating prompt, effec-
tive treatment. Information in this guide is designed to
assist clinicians to
• recognize common epidemiologic situations and clini-
cal manifestations of TBRD;
• obtain appropriate history and diagnostic tests for
TBRD;
• develop a differential diagnosis that includes and ranks
TBRD;
• make treatment decisions based on epidemiologic and
clinical evidence;
• recognize that doxycycline is the treatment of choice
for both adults and children;
• recognize that early and empiric antibiotic therapy can
prevent severe morbidity or death;
• identify the availability, limitations, and utility of con-
firmatory laboratory assays;
• recognize potential severe manifestations of TBRD; and
• report suspected and confirmed cases to appropriate
public health authorities to assist with control mea-
sures and public health education efforts.
This report also provides resources on TBRD for health-
care and public health professionals. Clinical cases are
included for self-evaluation and to reinforce the informa-
tion presented in this guide. Additional information con-
cerning TBRD in this report is available from medical
specialists, various medical societies, CDC, and state and
local health authorities.
Epidemiology of TBRD
RMSF, HME, and HGA are tickborne zoonoses caused by
Rickettsia rickettsii, Ehrlichia chaffeensis, and Anaplasma
phagocytophilum, respectively. These pathogens are maintained
in natural cycles involving wild mammals and hard-bodied
(ixodid) ticks. The epidemiologies of these diseases reflect
the geographic distribution and seasonal activities of the vec-
tors and reservoirs and the human behaviors that place per-
sons at risk for tick attachment and subsequent infection.
Selected epidemiologic and clinical features of TBRD have
been summarized (Table 1). RMSF, HME, and HGA are
reported each month of the year in the United States,
although 90%–93% of reported cases occur during April–
September (6,10–12), coincident with peak levels of tick
feeding activity on humans. Travelers outside of the United
States might also be exposed to other tick vectors in other
countries that transmit related agents that result in disease
after they return to the United States.
Males appear to be at higher risk for infection with all
TBRD, possibly because of greater recreational or occupa-
tional exposures to tick habitats. Although previous stud-
ies have indicated that the highest incidences of RMSF have
occurred in children aged <10 years, surveillance during
2003 demonstrates a higher age-specific incidence for
RMSF among persons aged 40–64 years, compared with
other age groups (13). For HME and HGA, the highest
age-specific incidences occurred among persons aged >70
and 60–69 years, respectively (14). The higher frequency
of disease reporting in adults might reflect greater suscep-
tibility to recognizable disease rather than higher infection
rates. Two recent cross-sectional studies in the southeast-
ern and south central United States* have indicated that
* Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah,
Nevada. East South Central: Kentucky, Tennessee, Alabama, Mississippi. East
North Central: Ohio, Indiana, Illinois, Michigan, Wisconsin. West South Central:
Arkansas, Louisiana, Oklahoma, Texas. West North Central: Minnesota, Iowa,
Missouri, North Dakota, South Dakota, Nebraska, Kansas. Pacific: Washington,
Oregon, California. New England: Massachusetts, Connecticut, Rhode Island,
New Hampshire. South Atlantic: Delaware, Maryland, Virginia, District of
Columbia, West Virginia, North Carolina, South Carolina, Georgia, Florida.
Mid-Atlantic: New York, New Jersey, Pennsylvania.
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FIGURE 1. An adult female Dermacentor variabilis (American
dog tick)
Photo/CDC
TABLE 1. Selected features of Rocky Mountain spotted fever,* human monocytotropic ehrlichiosis, human granulocytotropic
anaplasmosis,† and Ehrlichia ewingii infection — United States§
Incubation Common
Approximate period initial signs Common laboratory Case-fatality
Agent (disease) Primary vector(s) distribution¶ (days) and symptoms abnormalities Rash rate
Rickettsia rickettsii
(Rocky Mountain
spotted fever)
Ehrlichia
chaffeensis
(human
monocytotropic
ehrlichiosis)
Anaplasma
phagocytophilum
(human
granulocytotropic
anaplasmosis)
Ehrlichia ewingii
infection
* SOURCE: Walker DH, Raoult D. Rickettsia rickettsii and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett
JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2287–95.
† SOURCE: Walker DH, Dumler JS. Ehrlichia chaffeensis (human monocytotropic ehrlichiosis), Anaplasma phagocytophilum (human granulocytotropic anaplasmosis) and other
ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone;
2005:2310–8.
§ Treatment for each of these diseases is the same: adults, doxycycline 100 mg orally (PO) or intravenously (IV) twice daily; and children, doxycycline 2.2 mg/kg administered PO
or IV twice daily.
¶ Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada. East South Central: Kentucky, Tennessee, Alabama, Mississippi. East North Central: Ohio,
Indiana, Illinois, Michigan, Wisconsin. West South Central: Arkansas, Louisiana, Oklahoma, Texas. West North Central: Minnesota, Iowa, Missouri, North Dakota, South Dakota,
Nebraska, Kansas. Pacific: Washington, Oregon, California. New England: Massachusetts, Connecticut, Rhode Island, New Hampshire. South Atlantic: Delaware, Maryland,
Virginia, District of Columbia, West Virginia, North Carolina, South Carolina, Georgia, Florida. Mid-Atlantic: New York, New Jersey, Pennsylvania.
** SOURCE: Demma LJ, Traeger MS, Nicholson WL, et al. Rocky Mountain spotted fever from an unexpected tick vector in Arizona. N Engl J Med 2005;353:587–94.
Dermacentor variabilis
(American dog tick),
Dermacentor andersoni
(Rocky Mountain wood
tick), and Rhipicephalus
sanguineus (brown dog
tick) in AZ**
Amblyomma americanum
(lone star tick)
Ixodes scapularis and
Ixodes pacificus
(blacklegged tick) in the
United States
Amblyomma americanum
(lone star tick)
Widespread in the
United States,
especially South
Atlantic and South
Central states
South and Mid-
Atlantic, North/South
Central United States,
and isolated areas of
New England
New England, North
Central and Pacific
states
South Atlantic and
South Central United
States to isolated
areas of New England
2–14
5–14
5–21
5–14
Fever, nausea,
vomiting, myalgia,
anorexia, and
headache
Fever, headache,
malaise, and
myalgia
Fever, headache,
malaise, myalgia,
and vomiting
Fever, headache,
myalgia, nausea,
and vomiting
Thrombocytopenia,
mild hyponatremia, and
mildly elevated hepatic
transaminase levels
Leukopenia,
thromobocytopenia,
and elevated serum
transaminase levels
Leukopenia,
thrombocytopenia,
elevated serum
transaminase levels
Leukopenia,
thromobocytopenia,
and elevated serum
transaminase levels
Maculopapular rash
approximately 2–4
days after fever
onset in 50%–80%
of adults (>90% in
children); might
involve palms and
soles
Rash in <30% of
adults and
approximately 60%
of children
Rare
Rare
5%–10%
2%–3%
<1%
No
documented
fatalities
up to 22% of children have serologic evidence of previous
exposure to antigens of both E. chaffeensis (15) and
R. rickettsii (16), suggesting that rickettsial and ehrlichial
infection might be more common than previously recognized.
RMSF
In the United States, R. rickettsii is transmitted to
humans by several tick species. However, the species that
transmit R. rickettsii most frequently include the American
dog tick (Dermacentor variabilis; Figure 1) in the eastern,
central, and Pacific coastal United States and the Rocky
Mountain wood tick (Dermacentor andersoni; Figure 2) in
the western United States. In 2005, the brown dog tick
(Rhipicephalus sanguineus; Figure 3), a vector of RMSF in
Mexico (17), was implicated as a vector of this disease in a
confined geographic area in Arizona (18). The cayenne tick
(Amblyomma cajennense; Figure 4) is a common vector for
RMSF in Central and South America, and its range
extends into the United States in Texas (19). During 1997–
2002, the estimated average annual incidence of RMSF,
based on passive surveillance, was 2.2 cases per million
persons. More than half (56%) of reported cases of RMSF
were from only five states: North Carolina, South Caro-
lina, Tennessee, Oklahoma, and Arkansas (CDC, unpub-
lished data, 2005). However, cases have been reported from
each of the contiguous 48 states, except Vermont and Maine
(10,11). Average reported annual incidence of RMSF per
1 million population, based on cases reported to CDC dur-
ing 1997–2002, has been reported (Figure 5). Incidence
varies considerably by geographic area. RMSF is also
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FIGURE 5. Average reported annual incidence* of Rocky
Mountain spotted fever, by state — United States, 1997–2002
* Per 1,000,000 persons per year.
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FIGURE 6. An adult female Amblyomma americanum (lone
star tick)
Photo/CDC
FIGURE 3. An adult female Rhipicephalus sanguineus (brown
dog tick)
Photo/CDC
FIGURE 4. An adult male (left) and female (right) Amblyomma
cajennense (cayenne ticks)
Photo/J. Occi, Forestry Images, Athens, GA
endemic throughout several countries in Central and South
America, including Argentina, Brazil, Columbia, Costa Rica,
Mexico, and Panama (17,19,20). Household clusters of dis-
ease and hyperendemic foci of infected ticks have been
reported (3,21). Dogs are susceptible to RMSF, and they
might frequently develop the disease concurrently with
other household members in an endemic focus (22,23).
HME
E. chaffeensis is transmitted to humans by the lone star
tick, A. americanum (Figure 6), and possibly other ticks.
The white-tailed deer is a major host of all stages of lone
star ticks and is an important natural reservoir for
E. chaffeensis. Natural infections of coyotes, dogs, and goats
FIGURE 2. An adult female Dermacentor andersoni (Rocky
Mountain wood tick)
Photo/CDC
have been documented. The lone star tick is among the
most commonly encountered ticks in the southeastern
United States, with range extensions into areas of the South
Central and New England states (Figure 7). Cases of HME
are most commonly reported to CDC from Missouri, Okla-
homa, Tennessee, Arkansas, and Maryland, although the
disease is found throughout the range of the lone star tick.
The average reported annual incidence of HME was 0.7
cases per million population, but incidence varied by state,
based on cases reported to CDC from 2001 to 2002
(Figure 8). In a prospective study among febrile patients
with a history of a recent tick bite in central North Caro-
lina, the incidence of ehrlichial infection was approximately
twice that of RMSF (24). The reported incidence probably
represents an underestimate of the true burden of disease
in areas where E. chaffeensis is endemic (24,25). Clusters of
HME have been reported, suggesting that foci of ticks
infected with E. chaffeensis do occur (21,26).
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FIGURE 8. Average reported annual incidence* of human mono-
cytotropic ehrlichiosis, by state — United States, 2001–2002†
SOURCE: Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow
DL. Epidemiology of human ehrlichiosis and anaplasmosis in the United
States, 2001–2002. Am J Trop Med Hyg 2005;73:400–9.
* Per 1,000,000 persons per year.
†Nonreporting states do not have a value and appear white.
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FIGURE 9. An adult female Ixodes scapularis (blacklegged tick)
Photo/CDC
FIGURE 10. An adult female Ixodes pacificus (western black-
legged tick)
Photo/CDC
FIGURE 7. Approximate distribution of vector tick species
for human monocytotropic ehrlichiosis and human
granulocytotropic anaplasmosis
Ixodes scapularis
Ixodes pacificus
Amblyomma americanum
I scapularis A americanum
distribution
distribution
distribution
Overlapping distribution ( . and . )
HGA
The blacklegged tick (Ixodes scapularis; Figure 9) is the vec-
tor of A. phagocytophilum in New England and North Central
United States, whereas the western blacklegged tick (Ixodes
pacificus; Figure 10) is the principal vector in northern Cali-
fornia. Deer, elk, and wild rodents are thought to be reser-
voirs. HGA is more frequently reported than HME, resulting
in an average reported annual incidence of 1.6 cases per mil-
lion during 2001–2002. States that reported the highest
incidence during this period were Rhode Island (36.5 cases
per million), Minnesota (12.3 cases per million), Connecti-
cut (8.1 cases per million), New York (2.3 cases per million),
and Maryland (1.6 cases per million) (Figure 11). HGA has
been identified as a substantial cause of unexplained fever during
the tick season in Wisconsin (27). Evidence suggests that the
incidence of HGA in Wisconsin might be much higher than
that in Minnesota (7). Because these Ixodes species ticks also
transmit Borrelia burgdorferi (the causative agent of Lyme dis-
ease) and various Babesia species (agents of human babesio-
sis), the preponderance of cases of HGA occur in the same
states that report high incidences of Lyme disease and human
babesiosis. Simultaneous infection with A. phagocytophilum and
B. burgdorferi has been reported (28), and discerning such a
mixed infection is vital because it might affect antimicrobial
choice. For example, amoxicillin can be used to treat early
stage Lyme disease, but it is not effective for HGA.
Ehrlichia ewingii Infection
Amblyomma americanum also is the principal vector of
the ehrlichial pathogen, E. ewingii. The ecologic features of
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E. ewingii are not completely known; however, dogs and
deer have been naturally infected. Cases of granulocytotropic
ehrlichiosis caused by E. ewingii have been reported prima-
rily in immunocompromised patients from Missouri, Okla-
homa, and Tennessee (29,30). E. ewingii infections in dogs
or ticks also have been described in these states and in
Arkansas, Texas, Florida, Georgia, Mississippi, North Caro-
lina, and Virginia, suggesting that human infections with
this pathogen might be expected to occur throughout the
range of the lone star tick (31,32).
The following is a summary of the salient epidemiologic
features of TBRD:
• Occurrence is seasonal, with the majority of illness onset
during warmer spring and summer months, but cases
might develop throughout the year.
• RMSF has been reported in all of the contiguous 48
states, except Vermont and Maine.
• RMSF and HME are most commonly reported in the
southeastern and south central United States.
• HGA is reported most frequently in New England, the
north central states, and in focal areas along the West Coast.
Pathogen Tropisms
and Clinical Presentation
R. rickettsii, E. chaffeensis, E. ewingii, and A. phagocytophilum
have specific and distinct cell tropisms. R. rickettsii infects
endothelial cells and more rarely infects underlying smooth
muscle cells, where rickettsiae multiply freely in the cyto-
plasm. The rickettsiae cause a small-vessel vasculitis,
resulting in a maculopapular or petechial rash in the
majority of patients. Vasculitis occurring in organs (e.g.,
the brain or lungs) can result in life-threatening complica-
tions. R. rickettsii does not stain with the majority of rou-
tine histopathologic stains and is not detected by blood
smear evaluation because of limited numbers of circulating
bacteria. Ehrlichioses and anaplasmosis are characterized
by infection of leukocytes, where the causative agents mul-
tiply in cytoplasmic membrane-bound vacuoles as
microcolonies called morulae. E. chaffeensis most frequently
infects monocytes, whereas A. phagocytophilum and E. ewingii
demonstrate a predilection for granulocytes. Morulae may
be stained with conventional Wright or Giemsa stains and
are occasionally observed in leukocytes in smears of
peripheral blood, buffy coat preparations, or cerebrospinal
fluid. In this context, a routine blood smear can provide a
presumptive clue for early diagnosis; however, the visualiza-
tion of morulae still requires confirmatory testing for Ehrlichia
or Anaplasma species by serology, polymerase chain reaction
(PCR), or immunostaining methods (33). The demonstra-
tion of morulae is also not sensitive, and a case of ehrlichiosis
or anaplasmosis might be missed if the diagnosis relies solely
on detection of morulae on blood smears. Although the
diagnostic sensitivity of a blood smear is greater for HGA
than for HME, blood smears might only be positive in up to
60% of patients with HGA (34).
The following is a summary of salient features of patho-
gen tropisms:
• R. rickettsii infects endothelial cells, causing vasculitis,
which leads to rash and life-threatening damage to the
brain, lungs, and other viscera.
• R. rickettsii is not evident in blood smears, and these bacte-
ria and do not stain with the majority of conventional stains.
• Ehrlichia and Anaplasma species infect monocytes or granu-
locytes, respectively, and morulae might occasionally be
observed on peripheral blood smears by using routine stains.
Clues from the Clinical History
A thorough clinical history that elicits recent tick expo-
sure, specific recreational or occupational exposures to tick-
infested habitats, recent travel to areas where TBRD might
be endemic, or similar illnesses in family members, cowork-
ers, or pet dogs can provide critical information that can be
used to make a presumptive diagnosis of TBRD and help
guide subsequent therapeutic actions. However, the absence
of certain features does not exclude a diagnosis of TBRD.
FIGURE 11. Average reported annual incidence* of human
granulocytotropic anaplasmosis, by state — United States,
2001–2002†
Adapted from: Demma LJ, Holman RC, McQuiston JH, Krebs JW,
Swerdlow. Epidemiology of human ehrlichiosis and anaplasmosis in the
United States, 2001–2002. Am J Trop Med Hyg 2005;73:400–9.
* Per 1,000,000 persons per year.
†Nonreporting states do not have a value and appear white.
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These features include 1) history of tick bite or exposure,
2) recent travel to areas endemic for TBRD, and 3) similar
illness in family members, coworkers, or pets.
History of Tick Bite or Exposure
A detailed medical history might reveal activities that sug-
gest potential exposure to ticks. Outdoor activities during
April–September, particularly in areas with high uncut grass,
weeds, and low brush can increase the risk for tick bites
(35). These activities include recreational pursuits (e.g.,
camping, hiking, fishing, hunting, gardening, and walk-
ing dogs) as well as occupational activities that involve per-
sons being in brushy or grassy areas that might be inhabited
by ticks. Vegetation that borders roads, trails, yards, or fields
also are potential areas that might be inhabited by ticks. In
endemic areas (where the agents causing TBRD are present
at all times), even adults or children who play in grassy
areas in their backyard are at risk. Queries concerning fre-
quency of contact with family pets, especially dogs, and
findings of tick attachment to animals or removal can be
useful. The majority of patients will not recall or recognize
an attached tick because the location of the tick might be
obscure; the bite is typically painless; and bites from smaller
immature stages of ticks (e.g., nymphs are approximately
1–2 mm or the size of the head of a pin; Figure 12) might
not be readily detected but might still result in infection.
A specific history of a tick bite within 14 days of illness
onset is typically only reported in 60% of RMSF cases
(10,11) and has been reported in only 68% of ehrlichiosis
cases (6). Therefore, the absence of definite tick attachment
should never dissuade a physician from considering the
diagnosis of a TBRD. Finally, certain patients do not spe-
cifically recall tick exposure but might describe other pru-
ritic, erythematous, or ulcerated cutaneous lesions that they
call a mosquito bite, spider bite, chigger bite, or bug bite,
which can be indistinguishable from an actual tick bite.
Recent Travel to Areas Endemic
for TBRD
Clinicians in areas of the United States where the inci-
dence of TBRD is historically low are typically at a disad-
vantage in distinguishing these diseases among multiple
other infectious and noninfectious syndromes that they
resemble. Because TBRD are typically sporadic, identify-
ing these infections requires high clinical acumen, espe-
cially in an environment in which TBRD have not
previously been recognized as occurring frequently.
Knowledge of the epidemiology of these illnesses, includ-
ing regions of the country with a high incidence (number
of reported cases per million persons per year) of TBRD
(e.g., south Atlantic, north central, and south central and
New England states), is important. A history of recent travel
from an endemic area of TBRD (e.g., within 2 weeks pre-
ceding illness), especially if the patient had participated in
an outdoor activity, might support a suspicion of tickborne
illness. Physicians should also consider the possibility that
changes in tick vector range can influence the distribution
of TBRD. In addition, in 2004, a total of 13 cases of RMSF
occurred in eastern Arizona, a state in which the disease
was previously rarely diagnosed (18).
Clinicians should also consider that TBRD occur world-
wide and might have epidemiologic, seasonal, and clinical
features distinct from those observed in the United States.
International travel to destinations (e.g., southern Medi-
terranean, Central and South America, Africa, Asia, and
the Middle East) might result in tick vector exposure, par-
ticularly if the patient participated in rural or outdoor
activities. For example, African tick-bite fever (ATBF), an
increasingly reported travel-related rickettsiosis caused by
FIGURE 12. Comparison of Ixodes scapularis (blacklegged tick),
Amblyomma americanum (lone star tick), and Dermacentor
variabilis (American dog tick), by life stage*
Photo/CDC
* Ticks are shown in relative size to each other and to a dime.
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FIGURE 14. Eschar associated with Rickettsia parkeri infection
Photo/C.A. Ohl, Wake Forest University School of Medicine, Winston-Salem, NC
R. africae, has an estimated incidence of 4%–5.3% among
international travelers to sub-Saharan Africa and has been
identified in clusters of infection among group travelers (e.g.,
game hunters, safari tourists [36], and humanitarian work-
ers; 37). A related rickettsial organism, R. conorii, endemic
in the Mediterranean basin, Middle East, and parts of
Africa and the Indian subcontinent causes Mediterranean
spotted fever (MSF; 38). ATBF and MSF are characterized
by fever, malaise, headache, and myalgia, which are typical
symptoms for other TBRD. However, a distinguishing clini-
cal feature of both travel-related diseases is the develop-
ment of one or more eschars (a dark, scab-like plaque
overlying a shallow ulcer with surrounding erythema or
scaling) at the site of tick attachment that is noted coinci-
dent with or shortly after the onset of fever in 30%–50%
of patients (36,39).
Emerging TBRD
Similarly, considering TBRD as a diagnosis is essential
because of new, previously unrecognized rickettsial patho-
gens that have been observed in tick vectors in the United
States. For example, in 2002, R. parkeri was identified as a
new cause of spotted fever rickettsiosis in a patient living in
the southeastern coastal United States (40). This agent is
present in A. maculatum (the Gulf Coast tick; Figure 13),
which is found in the southeastern United States. A clini-
cal presentation, similar to ATBF and MSF (i.e., fever, head-
ache, eschars, and regional lymphadenopathy), was observed
in a patient with no substantial travel history (Figure 14).
The diagnosis of spotted fever rickettsiosis was confirmed
by using rickettsial culture from an eschar skin biopsy and
serologic and molecular methods (40). Other spotted fever
group rickettsiae might also cause mild febrile illness in
certain persons exposed to ticks in highly endemic areas
(41). The common observation of antibodies to rickettsiae
and ehrlichiae in persons and dogs might indicate expo-
sure to other rickettsial agents of varying pathogenicity
(15,16,24).
Similar Illness in Family Members,
Coworkers, or Pets
Clinicians might be inclined to offer diagnoses of a com-
municable viral infection when more than one family mem-
ber is affected by an illness. However, clustering of certain
TBRD is a well-recognized epidemiologic phenomenon and
might occur after exposure to natural foci of infected ticks.
Temporally and geographically related clusters occurring
among family members, coworkers, or persons frequenting
a particular common area have been observed. These clus-
ters include family clusters of RMSF (3), clusters of
ehrlichiosis among residents of a golfing community (26),
and soldiers on field maneuvers (21). Common exposures
to tick-infested habitats or outdoor activities might place
certain or all members of a family or group, including pet
dogs, at risk for TBRD. Concurrent infections with
R. rickettsii and Ehrlichia species also have been observed in
humans and dogs (22,24,29). Therefore, clinicians should
query patients concerning similar illnesses among family
members, close coworkers, or community residents, and
even among household dogs.
The following is a summary of salient features of clues
from the clinical history:
• A detailed history of recent recreational or occupational
activities might reveal potential exposure to ticks.
• Exposure can occur in the patient’s backyard or neigh-
borhood.
FIGURE 13. An adult female Amblyomma maculatum (Gulf
Coast tick)
Photo/CDC
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FIGURE 15. Maculopapular rash on the legs and feet of a
patient with Rocky Mountain spotted fever
Photo/G.S. Marshall, University of Louisville School of Medicine,
Louisville, KY
FIGURE 16. Late petechial rash on the forearm and hand of a
patient with Rocky Mountain spotted fever
Photo/CDC
• Familiarity with TBRD epidemiology will be helpful
when querying patients regarding recent travel to
endemic areas (domestic and international; 38,39).
• Clustering of certain TBRD is well-recognized and has
been reported among family members, coworkers, and
other defined groups.
Clinical Assessment
Signs and Symptoms
The early signs and symptoms of HME, HGA, RMSF,
and E. ewingii infection might resemble nonspecific find-
ings of other infectious and noninfectious diseases. The
majority of patients with TBRD visit a physician during
the first 2–4 days of illness, after an incubation period of
approximately 5–10 days after a tick bite (5). Patients with
HGA might seek medical care later (4–8 days after fever
onset) (7). Substantial overlap occurs in the initial clinical
presentation of the three diseases. Initial symptoms com-
monly include a sudden onset of fever, chills, and head-
ache, commonly associated with malaise and myalgia. In
adults, photophobia might be observed. Headache is nearly
always reported by adults who seek medical care and can
be severe. Patients also might report nausea, vomiting, and
anorexia early in the course of their illness, especially with
RMSF (35) and HME in children. Diarrhea might occa-
sionally occur. Other frequently observed signs and symp-
toms in children with either RMSF or HME are
abdominal pain, altered mental status, and conjunctival
injection. Abdominal pain might be severe enough to mimic
appendicitis or other causes of acute abdominal pain (42).
Certain findings described in medical textbooks are less
commonly observed by clinicians and include bilateral
periorbital edema, edema of the dorsum of hands and feet,
and calf pain and tenderness. Because the signs and symp-
toms that persons have when they first seek medical care
are nonspecific, clinicians frequently must incorporate clues
from the clinical and epidemiologic history and consider
other features (e.g., the presence of rash or abnormalities of
routine laboratory tests).
In RMSF, a rash typically appears 2–4 days after onset of
fever; however, the majority of patients will seek medical
care before this period. For adults and children with RMSF,
rash frequently occurs earlier in children than in adults
(43) and is eventually observed in approximately 90% of
children. The exanthem typically begins as small, blanch-
ing, pink macules on the ankles, wrists, or forearms that
evolve to maculopapules (Figure 15). In half of cases, the
rash might evolve to petechiae over the next several days of
illness. The classic centripetal spread of rash is typically
not noticed by the patient and might be difficult to elicit
from the clinical history. The rash can expand to involve
the entire body, including the palms and soles, but its pres-
ence on the face is usually limited. Discerning the rash in
darker-skinned persons might be difficult. The classic spot-
ted or generalized petechial rash of RMSF is usually not
apparent until the fifth or sixth day of the illness and signi-
fies progression of the disease, although the progression is
considerably variable (Figure 16). Patients with petechial
rash are often severely ill, and although fever and organ
dysfunction might resolve quickly with treatment, com-
plete recovery can take longer to occur. The rash progres-
sion of RMSF includes several critical exceptions and
considerations.
• A rash on the palms and soles is not pathognomonic
and might occur in illnesses caused by drug hypersen-
sitivity reactions, infective endocarditis, and a diverse
group of other agents, including Treponema pallidum,
Neisseria meningitidis, Streptobacillus moniliformis,
E. chaffeensis, and certain enteroviruses.
• The rash might be evanescent or localized to a particu-
lar region of the body.
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• A rash might be completely absent or atypical in up to
20% of RMSF cases (4,43,44).
Rash is observed in approximately one third of all
patients with HME (although rash is described in up to
66% of children) and is rare in patients with HGA or
E. ewingii infection (45,46). For children with HME and a
rash, distinguishing the condition from RMSF might be
difficult. Rash patterns occasionally associated with HME
vary in character from petechial or maculopapular
(Figure 17; 47) to diffuse erythema (48) and typically
occur later in the course of disease (median: 5 days after
onset; 6).The rash patterns might involve the extremities,
trunk, face or, rarely, the palms and soles (49).
In certain cases, patients with RMSF or ehrlichiosis might
seek medical attention for a febrile illness that mimics viral
meningoencephalitis. Focal neurologic deficits, including
cranial or peripheral motor nerve paralysis or sudden tran-
sient deafness, might also be observed (50).
Differential Diagnosis of Febrile Patients
with Rash
The differential diagnosis of febrile patients with rash is
broad. The onset of TBRD is frequently rapid, and the
majority of patients experience high fever, shaking chills,
severe headache, and generalized myalgias, in contrast to other
tickborne diseases (e.g., Lyme disease). Tickborne viral fevers
(e.g., Colorado tick fever) infrequently cause rash but should
be included in the differential diagnoses of TBRD, particu-
larly when leukopenia and thrombocytopenia are present in
a patient who has recently traveled to the western United
States. Clinically, TBRD might be essentially indistinguish-
able from the majority of viral infections, particularly those
in children. The dermatologic classification of the rash, its
distribution, pattern of progression and timing relative to
onset of fever, and other systemic signs provide clues that
help the clinician rule out other exanthemata. Maculopapu-
lar rashes might occur in association with multiple condi-
tions, including human herpesvirus 6 infection (i.e., roseola),
human parvovirus B19, enteroviral infection (e.g.,
coxsackievirus and echovirus), Epstein-Barr virus infection,
disseminated gonococcal infection, Mycoplasma pneumoniae
infection, leptospirosis, secondary syphilis, Kawasaki disease,
thrombotic thrombocytopenic purpura (TTP), drug reac-
tions, and immune complex-mediated illness (51). A pete-
chial rash can occur in association with meningococcal
infection, enteroviral infection, immune thrombocytopenic
purpura, and after group A streptococcal pharyngitis.
R. rickettsii infection is noted for causing a rash on the soles
and palms, although this distribution typically occurs late
in RMSF and in only half of cases, whereas in the majority
of other bacterial or viral infections rash has not been observed.
Initially, clinicians might experience difficulty distinguish-
ing N. meningitidis infection from RMSF because both can
begin as a maculopapular rash and progress to a petechial
rash, but the rash and other clinical features progress more
rapidly in meningococcemia than in RMSF. Selected infec-
tious causes and features of maculopapular and petechial rash
illnesses have been reported (Table 2). Other exanthema-
tous diseases that can occasionally be confused with TBRD
include toxic-shock syndrome, erythema multiforme, and
Stevens-Johnson syndrome.
Laboratory Findings
Obtaining a complete blood cell count (CBC), compre-
hensive metabolic panel, and examination of peripheral
blood smear are essential when considering a diagnosis of
TBRD. The total white blood cell (WBC) count is typi-
cally normal in patients with RMSF, but increased num-
bers of immature bands are generally observed.
Thrombocytopenia, mild elevations in hepatic transami-
nases, and hyponatremia might be observed with RMSF
(35), whereas leukopenia (up to 53% of patients), throm-
bocytopenia (up to 94% of patients), and modest eleva-
tions of liver transaminase levels are particularly suggestive
of HME and HGA (52,53). An inverse relation has been
reported between the mean WBC and platelet count and
the probability that HGA is the cause of nonspecific fever
(53). Blood smears might be useful in identifying patients
with HGA (34) or E. ewingii infection. Nonspecific changes
in the concentrations of routine laboratory parameters that
have been observed for patients infected with E. chaffeensis
(52) or A. phagocytophilum have been reported (53; Table 3).
Cerebrospinal fluid (CSF) analysis might be a useful
adjunct to laboratory diagnosis of TBRD. When CSF is
evaluated in patients with RMSF or HME, a pleocytosis
(usually <100 cells/microliter) is typically observed (with
FIGURE 17. Maculopapular rash associated with Ehrlichia
chaffeensis infection
Photo/D.J. Sexton, Duke University Medical Center, Durham, NC
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TABLE 2. Selected causes of fever and maculopapular or petechial rash*
Disease Agent Season Onset Clinical features
Rocky Mountain
spotted fever
Murine typhus
Monocytotropic
ehrlichiosis
Group A
streptococcal
pharyngitis
Meningococcal
disease
Fifth disease
(erythema
infectiosum)
Roseola
Enteroviral
infection
Rickettsia rickettsii
Rickettsia typhi
Ehrlichia chaffeensis
Group A Streptococcus
Neisseria meningitidis
Human parvovirus B19
Human herpesvirus 6
Echoviruses,
coxsackieviruses, and
other nonpolio
enteroviruses
Spring to summer
Sporadic
Spring to summer
Fall to winter
Year-round, but
especially late winter
to early spring
Late winter to early
summer
Year-round
Most common during
summer to early fall,
but occurs year-round
Fever, headache, malaise, and sometimes
gastrointestinal symptoms and rash after
2–4 days in >50% of patients
Fever, malaise, headache, and rash after
4–5 days in approximately 50% of
patients
Fever, malaise, headache, and rash in
approximately 30% of patients
Abrupt onset of fever and sore throat and
malaise; rash follows acute illness
Fever and rash (if bacteremic) within 24
hours
Low fever and mild constitutional signs
before rash onset
Fever 3–5 days then rash; most common
in children aged <2 years
Nonspecific febrile illness, with or without
rash
Rash usually starts peripherally and moves
centrally; might involve soles and palms;
progresses from maculopapular (MP†) to
petechial (P§)
MP rash frequently involving the trunk, with
involvement of extremities as well
Erythematous, MP, or P rash substantially
more common in children than in adults
Cause of P rash in children who appear well
MP and P rash usually begins on lower
extremities and moves centrally; early rash
might not have petechial component
“Slapped cheek” appearance of rash; lacy-
appearing rash on trunk
MP rash begins on trunk and spreads
elsewhere; fades rapidly
Fine MP rash appears at fever onset; begins on
face and spreads to chest and extremities;
might be P rash
* SOURCE: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Churchill Livingstone;
2005:1821–5, 1891–8, 2148–61, 2287–95, 2306–9, 2310–8, 2362–79, 2498–513.
† Maculopapular.
§ Petechial.
TABLE 3.  Changes in the concentrations of routine laboratory parameters observed in patients infected with Ehrlichia chaffeensis*
or Anaplasma phagocytophilum†
Laboratory parameter Days 1–7 Days 8–14 Days 15–28
Total white blood cells (absolute) Reduced Reduced to normal Normal
Segmented neutrophils (%) Increased Increased to normal Normal
Band neutrophils (%) Increased Increased to normal Normal
Lymphocytes (%) Reduced Normal to increased Increased to normal
Monocytes/eosinophils (%) Reduced Reduced to normal Normal
Platelets Reduced Reduced to increased Normal
C-reactive protein Increased Increased to normal Normal
Hepatic transaminases 2- to 4-fold increase Normal to mildly increased Normal
* SOURCE: Fishbein DB, Dennis DT. Tick-borne disease—a growing risk. N Engl J Med 1995;333:452–3.
†SOURCE: Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human
granulocytic ehrlichiosis. Clin Infect Dis 2001;32:862–70.
either a polymorphonuclear or lymphocytic predominance),
whereas CSF evaluated in E. ewingii infection is character-
ized by a neutrophilic pleocytosis (29). Moderately elevated
protein (100–200 mg/dL) and normal glucose levels also
are commonly observed in patients with RMSF (54,55).
A Gram stain indicating gram-negative diplococci, very low
glucose (i.e., <20–30 mg/dL), or neutrophilic pleocytosis
is more suggestive of meningococcal meningitis. Clinicians
should distinguish TBRD-related CNS involvement from
other infections (e.g., N. meningitidis); however, in the
majority of patients, reliably distinguishing between RMSF,
HME, and meningococcal infection based on laboratory test-
ing is difficult (unless a pathogen is cultured). Therefore,
empiric treatment for both TBRD and meningococcemia is
necessary for ill patients with fever and rash and for patients
in whom neither disease can be ruled out.
The following is a summary of salient clinical assessment
features:
• Early clinical presentations of HME, HGA, RMSF, and
E. ewingii infection include fever, headache, myalgia,
and malaise and are difficult to distinguish from other
infectious and noninfectious diseases.
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• Patients with RMSF typically do not have a spotted or
petechial rash when they initially seek medical care dur-
ing the first 2–4 days of illness.
• A CBC, metabolic panel, and peripheral blood smear
examination are helpful in developing both a differen-
tial diagnosis and treatment approach to TBRD.
• CSF analysis might reveal neutrophilic or lymphocytic
pleocytosis and elevated protein but might not reli-
ably distinguish TBRD and meningococcal disease,
necessitating empiric antibiotic therapy for both con-
ditions when indicated.
• Leukopenia, thrombocytopenia, mild hyponatremia,
and mildly elevated hepatic transaminase levels are com-
mon and particularly useful clinical features of TBRD,
although the absence of these features does not exclude
a diagnosis of TBRD.
• Infrequent features of TBRD include severe abdominal
pain and meningoencephalitis.
• Rash is observed frequently in RMSF, occasionally in
HME, and rarely in HGA or E. ewingii infection.
Treatment and Management
An assessment of clinical signs and symptoms, along with
laboratory diagnostic tests and a thorough clinical history,
will help guide clinicians in developing a differential diag-
nosis and treatment plan. At least 50% of patients with
TBRD might need to be hospitalized. Patients with evi-
dence of organ dysfunction and severe thrombocytopenia,
mental status changes, and the need for supportive therapy
should be hospitalized. Essential considerations include
social factors, the likelihood that the patient can and will
take oral medications, and existing comorbidities. For
example, a patient who appears well, has acute febrile ill-
ness and an unrevealing history and physical examination,
and whose laboratory indices are within normal limits might
warrant a “wait and watch” approach for 24 hours with
reassessment if the patient fails to improve. If laboratory
testing of a patient with a history compatible with TBRD
reveals leukopenia or thrombocytopenia, or metabolic
abnormalities, the clinician should consider obtaining blood
cultures for other likely pathogens and specific laboratory
tests and initiating empiric oral antimicrobial therapy that
will effectively treat TBRD. Certain patients with TBRD
can be treated on an outpatient basis with oral medication,
particularly if a reliable caregiver is available in the home
and the patient is compliant with follow-up medical care.
When other diagnoses are under consideration,
empiric treatment for these conditions can be incorporated
into the therapeutic plan. For example, for a patient’s con-
dition in which meningococcal disease cannot be ruled
out, intramuscular ceftriaxone should be administered in
addition to oral doxycycline to provide activity against pos-
sible meningococcal infection, pending culture results.
Inpatient observation and assessment of the blood cultures
after 24 hours of incubation should be considered for such
patients. A critical step is for clinicians to keep in close con-
tact with patients who are treated in the outpatient setting
to ensure that they are responding to therapy as expected.
Appropriate antibiotic treatment should be initiated
immediately when a clinician suspects that the diagnosis
could be RMSF, HME, HGA, or E. ewingii infection, based
on clinical, laboratory, or epidemiologic findings. Delay in
treatment can lead to severe disease and fatal outcome for
TBRD (2–4). Because each of the agents causing TBRD is
susceptible to tetracycline-class antibiotics, these drugs,
particularly doxycycline, are considered the therapy of
choice in nearly all clinical situations. Fever typically sub-
sides within 24–48 hours after treatment when the patient
receives doxycycline or another tetracycline during the first
4–5 days of illness. If a patient fails to respond to early
treatment with a tetracycline antibiotic (i.e., within 48
hours), this response might be an indication that their con-
dition is not a TBRD. Severely ill patients might require
longer periods before clinical improvement is noted, espe-
cially if they have multiple organ dysfunction.
Doxycycline is the drug of choice for treatment of all
TBRD in children and adults. This drug is bacteriostatic
in its activity against rickettsial organisms. The recom-
mended dose is 100 mg per dose administered twice daily
(orally or intravenously) for adults or 2.2 mg/kg body
weight per dose administered twice daily (orally or intra-
venously) for children weighing <100 lbs. (45.4 kg).
Intravenous therapy is frequently indicated for hospital-
ized patients, and oral therapy is acceptable for patients
considered to be early in the disease and who can be man-
aged as outpatients. Oral therapy also can be used for inpa-
tients who are not vomiting or obtunded. The optimal
duration of therapy has not been established, but current
recommendations for RMSF and HME are for treatment
for at least 3 days after the fever subsides and until evi-
dence of clinical improvement is noted, which is typically
for a minimum total course of 5–7 days. Severe or compli-
cated disease might require longer treatment courses.
Patients with HGA should be treated with doxycycline for
10–14 days to provide appropriate length of therapy for
possible incubating coinfection with Lyme disease (45).
The use of tetracyclines to treat children with TBRD is
no longer a subject of controversy (56–58). Concerns
regarding dental staining after tetracycline therapy have
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been based primarily on studies conducted during the
1960s that involved children receiving multiple courses of
the drug for recurrent otitis media (59,60). The propen-
sity of tetracyclines to bind calcium can lead to darkening
of the teeth if the antibiotic is ingested during the period
of tooth crown formation. More recent studies in 1971
and 1998, however, have demonstrated that although mul-
tiple exposures to tetracycline increase the risk for tooth
staining, limited use of this drug in children during the
first 6–7 years of life has a negligible effect on the color of
permanent incisors (56,57). Beyond ages 6–7 years, the
risk for tetracycline staining is of minimal consequence
because visible tooth formation is complete. Moreover, a
prospective study of children treated with doxycycline for
RMSF demonstrated that these children did not have sub-
stantial discoloration of permanent teeth compared with
those who had never received the drug (56). Because TBRD
can be life-threatening and limited courses of therapy with
tetracycline-class antibiotics do not pose a substantial risk
for tooth staining, the American Academy of Pediatrics
Committee on Infectious Diseases revised its recommen-
dations in 1997 and has identified doxycycline as the drug
of choice for treating presumed or confirmed RMSF and
ehrlichial infections in children of any age (61,62).
Chloramphenicol is an alternative drug that has been used
to treat RMSF (50); however, this drug is associated with
various side effects and might require monitoring of blood
indices. Chloramphenicol is no longer available in the oral
form in the United States. Moreover, epidemiologic studies
in which CDC case report data have been used suggested
that patients with RMSF treated with chloramphenicol
have a higher risk of dying than persons who received a
tetracycline (11,63). In vitro evidence also indicates that
chloramphenicol might not be an effective antibiotic for
HME or HGA (64,65). Clinicians who suspect a TBRD
and are considering empiric antibiotic therapy before labo-
ratory confirmation should be aware that doxycycline pro-
vides therapeutic coverage for RMSF, HME, HGA, and
E. ewingii infection.
Tetracyclines are generally contraindicated for use in preg-
nant women because of risks associated with malformation
of teeth and bones in the fetus and hepatotoxicity and pan-
creatitis in the mother (66). However, tetracycline has been
used successfully to treat HME in pregnant women (67),
and the use of tetracyclines might be warranted during preg-
nancy in life-threatening situations where clinical suspi-
cion of TBRD is high. Whereas chloramphenicol is typically
the preferred treatment for RMSF during pregnancy, care
must be used when administering chloramphenicol late
during the third trimester of pregnancy because of risks
associated with grey baby syndrome (66). Substantially lim-
ited clinical data exist that support the use of other antimi-
crobials during pregnancy, although rifampin has been used
successfully in several pregnant women with HGA (68). In
vitro studies have demonstrated that rifamycins provide
effective activity against Ehrlichia and Anaplasma species
(64,65), and therapy with rifampin may be considered for
patients with HGA who are unsuited for tetracycline treat-
ment because of pregnancy or a history of drug allergy (45).
Clinicians should use caution, however, in ensuring that
RMSF can be ruled out because the clinical presentations
of RMSF and anaplasmosis are similar, and the compara-
tive effectiveness of rifampin and doxycycline is unknown
at this time.
Because certain patients with TBRD might initially
receive an alternative diagnosis, they might be empirically
treated with antibiotics inactive against rickettsiae, includ-
ing penicillins, cephalosporins, aminoglycosides, erythro-
mycin, or sulfonamides. This situation presents both
diagnostic and therapeutic challenges. In certain cases,
patients treated with beta-lactam antibiotics or sulfa-
containing drugs are mistakenly thought to have drug erup-
tions when they later manifest a rash (66), further postponing
a correct diagnosis and appropriate treatment. Because the
physician might conclude that the prescribed treatment
will take time to work, a delay in obtaining critical addi-
tional laboratory or clinical information also might be a result.
In addition, sulfa-containing antimicrobials have been associ-
ated with increased severity of TBRD, although whether dis-
ease severity is directly related to the use of sulfa-containing
drugs or the delayed administration of more effective antimicro-
bials is not clear. Cases of severe ehrlichiosis complicated by acute
respiratory distress syndrome have been associated with the use of
trimethoprim-sulfamethoxazole (69,70).
In addition, clinicians should note the overlap between
early symptoms of invasive meningococcal infection and
TBRD. These conditions are difficult to distinguish early
in the course of illness. In patients for whom both condi-
tions are included in the initial differential diagnoses, after
performing blood cultures and a lumbar puncture, empiri-
cally treating for both diseases is appropriate. This treat-
ment can be accomplished by adding an appropriate
parenteral penicillin or cephalosporin that has activity
against N. meningitidis to doxycycline therapy.
Preventive antibiotic therapy for rickettsial infection is
not indicated for patients who have had recent tick bites
and are not ill. Limited numbers of ticks in areas where
tickborne diseases are endemic are infected with pathogenic
rickettsiae. Approximately 1%–3% of vector ticks are
infected with spotted fever group rickettsiae (71). How-
14 MMWR March 31, 2006
FIGURE 18. Digital necrosis affecting the toes of a patient,
occurring late in the course of Rocky Mountain spotted fever
Photo/G.S. Marshall, University of Louisville School of Medicine, Louisville, KY
ever, less than 1% of these rickettsiae usually have been
confirmed to be R. rickettsii (72,73). Approximately
5%–15% of lone star ticks are infected with E. chaffeensis (47),
and 10%–50% of I. scapularis ticks are reported to be
infected with A. phagocytophilum (74,75) in endemic areas.
Therefore, the risk for such infection after a tick bite is low.
Moreover, for RMSF, preventive therapy has been demonstrated
to delay but not prevent the onset of symptoms (76).
The following is a summary of salient features of treat-
ment and management:
• Clinical history, symptoms, and physical and labora-
tory findings should guide the clinician’s approach to
patient management and treatment.
• Not all patients with TBRD will require hospitalization.
• Clinicians may consider a wait and watch approach for
24–48 hours for patients early in the course of illness
and who have nonsupporting history, nonspecific clini-
cal signs, and normal laboratory findings.
• Doxycycline is the drug of choice for the treatment of pre-
sumptive or confirmed TBRD in both adults and children.
• Limited courses of tetracycline-class antibiotics (e.g.,
doxycycline) do not pose a substantial threat of tooth
staining in children.
• Tetracyclines typically are contraindicated for use
during pregnancy but might be warranted in life-
threatening situations where clinical suspicion of TBRD
is high.
• Delay in treatment can lead to severe disease and fatal
outcome of TBRD.
• In evaluating for TBRD, when early invasive meningo-
coccal infection cannot be ruled out, providing treat-
ment for both conditions by adding an antimicrobial
that has activity against N. meningitidis is appropriate.
• Prophylactic use of antibotics after a tick bite is not
recommended.
Considerations for Management
of Patients with Severe
Manifestations of TBRD
A substantial number of patients with TBRD require hos-
pitalization (6,7,10). Severe manifestations of TBRD might
include prolonged fever, renal failure, disseminated intra-
vascular coagulopathy (DIC), hemophagocytic syndrome,
meningoencephalitis, and acute respiratory distress syn-
drome. A notable exception is that HGA has not been asso-
ciated with meningoencephalitis.
RMSF is frequently a severe illness, and patients com-
monly require hospitalization. Up to 20% of untreated cases
and 5% of treated cases have fatal outcome, making RMSF
the most commonly fatal rickettsial disease in the United
States (5,10). However, assessment of passive reporting of
RMSF-associated death has suggested that only one third
of fatal cases of RMSF were reported to CDC during 1983–
1998 (77). Therefore, the actual case-fatality rate of RMSF
might be closer to 5%–10%. Host factors associated with
severe or fatal RMSF include advanced age, male gender,
black race, chronic alcohol abuse, and glucose-6-phosphate-
dehydrogenase (G6PD) deficiency (50). Deficiency of
G6PD is a sex-linked genetic condition affecting approxi-
mately 12% of the U.S. black male population; deficiency
of this enzyme is associated with a high proportion of ful-
minant cases of RMSF (50,78). Fulminant cases follow a
clinical course that is fatal within 5 days of onset. Long-
term health effects persisting for >1 year after acute RMSF
infection include partial paralysis of the lower extremities;
gangrene requiring amputation of fingers, toes, arms, or
legs; hearing loss; blindness; loss of bowel or bladder con-
trol; movement disorders; and speech disorders (79). These
complications are observed most frequently in persons
recovering from severe, life-threatening disease, often after
lengthy hospitalizations. Digital necrosis in a patient
occurring late in the course of RMSF has been illustrated
(Figure 18).
Similarly, HME and HGA can cause serious or fatal dis-
ease as well, although at lower rates than are observed for
RMSF. At least 50% of patients with HGA and HME are
hospitalized to rule out other potentially life-threatening
conditions and to manage the illness (34,47). Clinical
indications for admission might include immunocompro-
mised state, pain management (i.e., headache and myalgias),
mental confusion, cough, infiltrate in chest radiograph,
abnormal spinal fluid findings, or specific acute organ fail-
ure. Approximately 3% of HME patients and less than 1%
of HGA patients with symptoms severe enough to seek
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medical attention will die from the infection (25,34,47).
The severity of ehrlichiosis might be related, in part, to the
immune status of the patient. Persons with compromised
immune systems caused by immunosuppressive therapies
(e.g., corticosteroids or cancer chemotherapy), human
immunodeficiency virus (HIV) infection, organ transplan-
tation, or splenectomy appear to develop more severe dis-
ease from E. chaffeenis infection, and case-fatality rates for
these persons are characteristically higher than case-
fatality rates reported for the general population (30).
Although the case fatality rate for HGA (0.5%–1.0%) is
lower than that for HME, notable complications, includ-
ing respiratory failure, a toxic-shock–like syndrome,
rhabdomyolysis, pancreatitis, acute renal failure, and inva-
sive infections caused by opportunistic viral or fungal agents
can occur, especially among patients who have co-morbid
illnesses or who are actively immunosuppressed (45). In
addition, advanced patient age and delay in diagnosis and
the onset of specific antibiotic therapy are predictors of a
more severe course of HGA (53).
Management of severely ill patients with TBRD should
include careful assessment of fluid and electrolyte bal-
ance. Vasopressors and rigorous fluid management might
be needed, especially when the illness is complicated by
renal failure or hypotension. Patients might have pulmo-
nary infiltrates because of vasculitis that are erroneously
thought to be caused by cardiac failure or pneumonia. Sei-
zures might require aggressive treatment, and arrhythmias
(e.g., atrial fibrillation or flutter) will frequently respond
to treatment of the patient’s underlying disease. Consulta-
tion with an intensivist or an infectious disease subspecialist
might be helpful in managing these complications.
The following is a summary of salient features of severe
manifestations:
• TBRD can be life-threatening.
• Severe manifestations of TBRD include prolonged fever,
renal failure, myocarditis, meningoencephalitis,
hypotension, acute respiratory distress syndrome, and
multiple organ failure.
Confirmatory Diagnostic Tests
Rickettsial infections pose difficult diagnostic challenges
to both clinicians and laboratorians. Rapid confirmatory
assays are not commonly available to guide treatment deci-
sions of acutely ill patients. However, confirmatory assays
provide the physician with vital information that retrospec-
tively validates the accuracy of the clinical diagnosis. Labora-
tory confirmation of infection is also vital to understanding
the epidemiology and public health impact of TBRD.
Several laboratory methods are available to diagnose
TBRD. However, they vary in the time required to obtain
results and in the type of information they provide the cli-
nician. Therefore, treatment decisions should be based on
epidemiologic and clinical clues and should never be
delayed while waiting for laboratory confirmation of a
diagnosis. Similarly, test results should be interpreted in
the context of the patient’s illness and the epidemiologic
setting. Misuse of specialized tests for patients with a low
probability of the disease and in areas with a low preva-
lence of disease might result in confusion. A fundamental
understanding of the signs, symptoms, and epidemiology
of the disease is critical in guiding requests for tests and
interpretation of test results for ehrlichioses, anaplasmosis,
and RMSF. Studies have suggested that antibiotic therapy
might diminish the development of convalescent
antibodies in RMSF (CDC, unpublished data, 2005). How-
ever, the degree to which doxycycline might cause this
occurrence is uncertain. If molecular or culture diagnostic
methods are conducted, obtaining blood for testing before
antibiotics are administered is essential to obtain the best
results.
Blood-Smear Microscopy
Microscopic examination of blood smears stained with
eosin-azure type dyes (e.g., Wright-Giemsa stain) might
reveal morulae in the cytoplasm of infected circulating leu-
kocytes (1%– 20%) of patients with HME and 20%–80%
of patients with HGA (45,47) during the first week of
infection, which is highly suggestive of ehrlichial or ana-
plasma infection. However, blood smear examination is
insensitive and should be performed by an experienced
microscopist. In addition, a negative blood smear exami-
nation should not dissuade the caregiver from initiating
treatment with doxycycline if the clinical presentation and
routine laboratory findings support the diagnosis of
ehrlichiosis or anaplasmosis. Blood smear examination is
not useful for diagnosis of RMSF.
Serologic Testing
Serologic assays for RMSF, HME, and HGA are commonly
available through multiple commercial and state public
health laboratories. Serologic evaluations are commonly con-
ducted by using the indirect immunofluorescence antibody
(IFA) assay. Antibodies in the serum bind to fixed antigens
on a slide and are detected by a fluorescein-labeled conju-
gate. Although IFA remains the principle diagnostic tool for
the diagnosis of rickettsial and ehrlichial infections, no stan-
dardized antigens, conjugates, or agreement on what consti-
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tutes a positive result among the various laboratories provid-
ing these tests exist. Individual laboratories should be con-
sulted regarding their test threshold levels. Enzyme-linked
immunosorbent assay (ELISA) is becoming a more frequently
used assay. Similar to IFA, the accuracy of ELISA depends
on the laboratory conducting the test, the quality and speci-
ficity of the antigen, and the threshold levels at which a posi-
tive result is considered. Available ELISA tests are qualitative
and cannot be used effectively to monitor increases or
decreases in antibody titer.
The sensitivity of the IFA assay is substantially depen-
dent on the timing of collection of the sample. Early in
any TBRD, a majority of serologic tests will be negative.
Clinical illness nearly always precedes laboratory diagnosis
by any method. As the illness progresses to 7–10 days, the
sensitivity of IFA serology increases. The IFA is estimated
to be 94%–100% sensitive after 14 days, and that sensi-
tivity is increased if paired samples are tested (80). The IFA
is considered to be the gold standard of serologic testing
for rickettsial diseases, and other serologic tests have not
been developed that surpass the sensitivity and specificity
of these assays. Testing two sequential serum or plasma
samples together to demonstrate a rising IgG or IgM anti-
body level is essential to confirm acute infection. Paired
serum specimens taken early (i.e., acute) and later (i.e.,
convalescent) in the disease course represent the preferred
specimens for evaluation. Typically, these specimens should
be taken at least 2–3 weeks apart to examine for a four-fold
or greater increase in antibody titer (33).
The majority of patients demonstrate increased IgM or
IgG titers by the second week of the illness (patients
infected with certain imported rickettsiae might not dem-
onstrate increased titers until 4 weeks after illness onset).
However, patients might lack diagnostic IgG and IgM anti-
body titers in the first 7 days of illness, a period when the
majority of patients initially seek medical care and labora-
tory testing is performed. The duration of time that anti-
bodies will persist after recovery from the infection is variable.
In certain persons, high titers of antibodies against
A. phagocytophilum have been observed for 3½ years after the
acute illness (81). For RMSF, IgG and IgM titers
increase concurrently by the second week of illness, and IgM
antibodies wane after 3–4 months, whereas IgG titers per-
sist for 7–8 months (82). The majority of commercial refer-
ence laboratories conduct testing for IgG and IgM antibodies.
Cross-reactivity of antigens results in antibody responses
that are typically group-specific, but not necessarily spe-
cies-specific, after infections with these pathogens. For
example, serologic tests that detect antibodies reactive with
R. rickettsii might have resulted from previous infections
with other spotted fever group rickettsial species. Similarly,
antibodies reactive with E. chaffeensis or A. phagocytophilum
occasionally react with the other ehrlichial species, which
might impede epidemiologic distinction between the
ehrlichial infections (83). Most patients with E. ewingii
infections develop antibodies that react with E. chaffeensis
antigens. Little cross-reactivity of Rickettsia with Ehrlichia
or Anaplasma species exists. Certain serologically confirmed
cases of infection thought to be RMSF, HME, or HGA
might represent infections with the other agent or with
another antigenically related species. The predominance of
non-R. rickettsii species in tick vectors collected in RMSF-
endemic areas suggests that related organisms of undeter-
mined pathogenicity might play a role in human illness
(84). This occurrence is especially true for persons who are
infected with rickettsial organisms from endemic areas out-
side of the United States.
Nucleic Acid Detection
Amplification of specific DNA by PCR provides a rapid
method for detecting TBRD infections. These tests are avail-
able from CDC, certain state health laboratories, and a lim-
ited number of research and commercial laboratories (Box).
Conventional PCR tests have no specified standard, and
diagnostic sensitivity and specificity might vary among
individual assays (80). Doxycyline treatment, in particu-
lar, can also decrease the sensitivity of PCR (45). In studies
of A. phagocytophilum infection, PCR was estimated as 60%–
70% sensitive (53), and for diagnosis of infection with
E. chaffeensis, PCR was estimated to be 52%–56% sensi-
tive (25) to 87% sensitive (85). For RMSF, PCR is prob-
ably more useful for detecting the etiologic agent in a skin
biopsy or autopsy tissue specimen than it is in an acute
blood sample because, typically, low numbers of rickett-
siae circulate in the blood in the absence of advanced dis-
ease or fulminant infection (18). PCR testing of skin
biopsies alone does not offer ideal sensitivity, and a nega-
tive result does not exclude the diagnosis because of focality
of vessel involvement. Laboratory confirmation of RMSF
in the acute stage is improved when PCR is used in con-
junction with IHC staining. PCR of whole blood speci-
mens is more useful for confirming HME, HGA, and
E. ewingii infection because of the tropism of these patho-
gens for circulating WBC. However, no optimal time frame
has been established that is ideal for sample collection to
ensure the highest sensitivity for diagnosing ehrlichioses or
anaplasmosis. New techniques (e.g., real-time PCR) might
offer the advantages of speed, reproducibility, quantitative
Vol. 55 / RR-4 Recommendations and Reports 17
BOX. Websites of organizations that provide tickborne rickettsial disease (TBRD) testing, laboratory safety, and general information
CDC
Viral and Rickettsial Zoonoses Branch http://www.cdc.gov/ncidod/dvrd/ehrlichia/index.htm
National Center for Infectious Diseases http://www.cdc.gov/ncidod/dvrd/rmsf/index.htm
Laboratories Performing Diagnostic Assays
Association of Public Health Laboratories http://www.aphl.org/about_aphl/state_laboratory_listing.cfm
Laboratory Safety
CDC Select Agent Program http://www.cdc.gov/od/sap
Biosafety in Microbiological and Biomedical Laboratories http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm
General Information Regarding TBRD
Council of State and Territorial Epidemiologists http://www.cste.org
The American Society for Rickettsiology http://www.cas.umt.edu/rickettsiology
capability, and low risk for contamination, compared with
conventional PCR (86).
IHC Staining
Another approach to diagnosing TBRD is immunohis-
tochemical (IHC) staining of antigens in formalin-fixed,
paraffin-embedded biopsy or autopsy tissues. This test can
be particularly useful to diagnose fatal TBRD in those
patients for whom diagnostic levels of antibodies have not
developed before death. For patients with a rash, IHC or
immunofluorescence staining of a skin biopsy can be a criti-
cal diagnostic technique for RMSF. Immunostaining of skin
biopsy specimens has been reported to be 100% specific
and 70% sensitive in diagnosing RMSF (35). This method
has been used to diagnose fatal and nonfatal cases of RMSF
(18,87–89). Because rickettsiae might be focally distrib-
uted in tissue, this test might not always detect the agent.
Autopsy tissues also are appropriate for evaluation and
include the liver, spleen, lung, heart, kidney, and brain.
The IHC method is most useful in documenting the pres-
ence of organisms in patients before initiation of antibiotic
therapy or within the first 48 hours after antibiotic therapy
has been initiated. IHC techniques also are available for
diagnosing cases of ehrlichioses and anaplasmosis from bone
marrow biopsies and tissue obtained at autopsy of fatal cases,
including the spleen, lymph nodes, liver, and lung
(90–92). Immunostaining for spotted fever group rickett-
siae, E. chaffeensis, and A. phagocytophilum is offered by CDC
and certain university-based hospitals and commercial labo-
ratories in the United States (Box).
Culture
Because the agents that cause TBRD are obligate intracel-
lular pathogens, they must be isolated by using cell culture
techniques that are typically more labor-intensive and time-
consuming than serologic, molecular, or IHC assays. Theo-
retically, any laboratory capable of performing routine viral
isolations might have the expertise to isolate these patho-
gens. However, R. rickettsii is classified as a Biosafety Level-3
(BSL-3) agent, and attempts to isolate this agent should be
made only in laboratories equipped to handle BSL-3 patho-
gens (93). Laboratories attempting culture of R. rickettsii bac-
teria need to comply completely with federal regulations
(42 C.F.R. [2004]) regarding the registration and use of
select agents (93). As a result, culture is rarely used for diag-
nosis, and other methods (e.g., serology, PCR, or immuno-
staining) are used to confirm infection.
The following is a summary of salient features of diag-
nostic testing:
• Blood smear microscopy might reveal presence of moru-
lae in infected leukocytes, which is highly suggestive
of HGA or, less commonly, HME.
• Blood smears are not useful to diagnose RMSF.
• Examination of paired serum samples obtained 2–3
weeks apart that demonstrate a rise in antibody titer is
the most appropriate approach to confirm TBRD.
• Patients usually do not have diagnostic serum antibody
titers during the first week of illness; therefore, an
inability to detect antibodies (IgG or IgM) in acute-
phase serum does not exclude TBRD.
• Immunohistochemistry of a biopsied skin lesion or
autopsy tissues is useful for RMSF diagnosis in patients for
whom diagnostic titers of antibodies have not yet developed.
18 MMWR March 31, 2006
TABLE 4. Case definitions for Rocky Mountain spotted fever,* human monocytotropic ehrlichiosis (HME), human granulocytotropic
anaplasmosis (HGA), and unspecified ehrlichiosis†
Rocky Mountain spotted fever Ehrlichiosis and anaplasmosis
* SOURCE: CDC. Rocky Mountain spotted fever (Rickettsia rickettsii): 2004 case definition. Atlanta, GA: US Department of Health and Human Services, CDC, Epidemiology Program
Office, Division of Public Health Surveillance and Informatics; 2004.
† SOURCE: CDC. Ehrlichiosis (HGE, HME, other or unspecified): 2000 case definition. Atlanta, GA: US Department of Health and Human Services. CDC, Epidemiology Program
Office, Division of Public Health Surveillance and Informatics; 2000.
§ Indirect immunofluorescence antibody.
¶ Enzyme-linked immunosorbent assay.
** Immunohistochemical.
†† Polymerase chain reaction.
Tickborne illness characterized by acute
onset of fever and possible headache,
malaise, myalgia, and nausea/vomiting or
neurologic signs. A macular or maculopapu-
lar rash is reported in the majority of
patients and is frequently observed on the
palms and soles.
Clinical
description
Tickborne illness characterized by acute onset of fever, headache, myalgia, and possible malaise. Nausea,
vomiting, or rash might be observed in certain cases. Clinical laboratory findings might include thrombocy-
topenia, leukopenia, and possibly elevated liver enzymes. Intracytoplasmic morulae might be visible in the
leukocytes of certain patients.
Laboratory
criteria
HME HGA Unspecified ehrlichiosis
Serologic evidence of 4-fold change in
serum antibody titer against Rickettsia
rickettsii antigens between paired serum
samples, as determined by IFA§
or ELISA¶;
or
demonstration of R. rickettsii antigen in
a clinical specimen by IHC** methods;
or
detection of R. rickettsii DNA in a clinical
specimen by PCR assay;
or
isolation of R. rickettsii from a clinical
specimen in cell culture.
Probable case: Identified in a person with
a clinically compatible illness and serologic
evidence of antibody reactive with R.
rickettsii in a single serum sample at a titer
considered indicative of current or previous
infection (cutoff titers are determined by
individual laboratories).
Demonstration of 4-fold change in
antibody titer to Ehrlichia chaffeensis
antigen by IFA in paired serum samples;
or
positive PCR†† assay and confirmation
of E. chaffeensis DNA;
or
identification of morulae in leukocytes
and a positive IFA titer to
E. chaffeensis antigen;
or
immunostaining of E. chaffeensis
antigen in a biopsy or autopsy sample;
or
culture of E. chaffeensis from a clinical
specimen.
Demonstration of 4-fold change
in antibody titer to Anaplasma
phagocytophilum antigen by IFA
in paired serum samples;
or
positive PCR assay and confirmation
of A. phagocytophilum DNA;
or
identification of morulae in leukocytes,
and a positive IFA titer to
A. phagocytophilum antigen;
or
immunostaining of A. phagocytophilum
antigen in a biopsy or autopsy sample;
or
culture of A. phagocytophilum from a
clinical specimen.
Demonstration of 4-fold
change in antibody titer to
more than one Ehrlichia
species in which a
dominant reactivity cannot
be established;
or
Identification of a species
other than E. chaffeensis
or A. phagocytophilum by
PCR, immunostaining, or
culture.
Case
classification
Probable case: Identified in a person with a clinically compatible illness with either a single positive IFA titer
(based on cutoff titers established by the laboratory performing the test) or the visualization of morulae in
leukocytes.
Confirmed case: Identified in a person with a clinically compatible illness that is laboratory confirmed by a 4-fold change in serum antibody titer, as
determined by IFA or ELISA or positive PCR or positive IHC, or isolation in culture.
• Whole blood specimens might be useful for a PCR con-
firmation of HME, HGA, and E. ewingii infection; how-
ever, a negative result does not rule out the diagnosis.
Surveillance and Reporting
National reporting requirements are determined
collaboratively by the Council of State and Territorial Epi-
demiologists and CDC. RMSF, anaplasmosis, and all forms
of ehrlichiosis are nationally notifiable diseases. RMSF
became nationally notifiable in 1989 and anaplasmosis and
ehrlichiosis, in 1998. When health-care providers identify
a potential case of TBRD, they should notify the local health
department. The local health department, in cooperation
with the state health department, can assist the health-
care provider in obtaining appropriate diagnostic testing
to confirm the diagnosis. All confirmed or probable cases
of RMSF, HME, HGA, and E. ewingii infection should be
reported to the state health department. The case defini-
tions for confirmed and probable cases of RMSF, HME,
and HGA have been reported (Table 4; 33,94). Each state
health department compiles case reports and submits them
to CDC, where data are compared and disseminated via
the MMWR Weekly and annual Surveillance Summaries.
Since 1981, CDC has collected and analyzed surveillance
data on RMSF by using two complementary systems. States
submit reports electronically via the National Electronic
Telecommunications System for Surveillance (NETSS) as
part of the National Notifiable Disease Surveillance Sys-
tem. NETSS reports capture diagnosis, date of onset, and
basic demographic and geographic data related to the case.
In addition, physicians are encouraged to complete a stan-
dardized case report form (CRF; Appendix) and forward it
to the state health department, where it is compiled with
similar reports and forwarded to CDC. The CRF summa-
rizes demographic, epidemiologic, and outcome data that
are not reported in NETSS. Data collected on the CRF are
useful in summarizing the epidemiologic characteristics of
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tion per application. Products with DEET concentrations
as low as 10% and those containing 25%–35% concentra-
tions are considered optimal. No evidence exists that con-
centrations >50% are more efficacious or provide longer
duration of protection (95). The American Academy of
Pediatrics has recommended that DEET concentrations no
greater than 20%–30% should be used for children (96).
Products containing permethrin (e.g., permanone) can be
used to treat outer clothing (e.g., shirts and pants) and should
not be applied to skin. Permethrin is available commercially
as a spray-on preparation. It should be applied evenly to
outer clothing, according to label directions in a well-
ventilated area. Clothing should be allowed to completely
dry before being worn. Pre-treated clothing is available and
remains effective for multiple launderings. The use of DEET
and permethrin should be considered by persons who enter
heavily infested tick habitats where the risk for being bitten
is high and the potential for TBRD infection exists.
Adults entering wooded or grassy areas should inspect
themselves and their children frequently for ticks. Because
several hours might elapse before ticks attach and inject
pathogens, frequent checks increase the likelihood of find-
ing ticks before they transmit an infectious agent. The
duration of tick attachment necessary to transmit rickett-
sial organisms is substantially variable and has been reported
to be as little as 2–10 hours (97) to 10–20 hours (98) for
R. rickettsii. Limited data exist regarding the interval of trans-
mission after tick attachment for A. phagocytophilum, but
animal studies indicate that 24–48 hours might elapse
before pathogen transmission (99,100). No comparable
data exists for E. chaffeensis. Sites where ticks commonly
attach include, but are not limited to, the scalp, waist,
armpits, groin, and under socks and the beltline. Pets should
also be checked for ticks because they can carry ticks back
to their homes and human companions. Regular applica-
tion of ectoparasite control on pets helps to reduce the risk
for human exposure to ticks.
If an attached tick is found, it should be removed by
grasping with tweezers or fine-tipped forceps close to the
skin and gently pulling with constant pressure. Folk rem-
edies, including gasoline, kerosene, petroleum jelly, fin-
gernail polish, or lit matches should never be used to extract
ticks (101). Removing the tick with bare hands should be
avoided because fluids containing infectious organisms
might be present in the tick’s body and at the wound site.
Ticks that have been removed should not be crushed
between the fingers to prevent contamination, and hands
should be washed to avoid potential conjunctival inocula-
tion. The bite wound should then be disinfected.
disease and focusing on prevention and treatment. This
process includes examining lesser understood aspects of
these conditions (e.g., the role of immunosuppression as a
risk factor for disease; the prevalence of severe outcomes of
infection, including death; and hospitalization trends). In
2001, the form was expanded to include reporting of other
common TBRD, including HGA and HME, in addition
to RMSF.
A surveillance system is critical for studying the changing
epidemiology of TBRD and for developing effective preven-
tion strategies and public health education programs. The
detection of a cluster of RMSF cases in a region of Arizona
where the disease was not known to occur and subsequent
prevention and control initiatives underscore the vital role of
surveillance and reporting in protecting the public’s health.
By the end of 2004, the highest number of RMSF cases
was reported to CDC (n = 1,514), suggesting potential
increased activity. However, underreporting of TBRD is prob-
ably common.
The following is a summary of salient features of surveil-
lance and reporting:
• RMSF, HME, HGA, and other ehrlichioses are report-
able diseases in the United States.
• Physicians who identify a potential case of TBRD should
notify the local health department, which can assist with
obtaining diagnostic testing to confirm the diagnosis.
• Surveillance and reporting of TBRD are key compo-
nents of public health education and disease preven-
tion efforts.
Prevention
No licensed vaccines for TBRD exist. Avoiding tick bites
and promptly removing attached ticks remain the best dis-
ease prevention strategies. Persons should limit their expo-
sure to tick-infested habitats, including wooded or grassy
areas. Persons should walk on cleared trails and avoid brush-
ing against tall grass and other vegetation. This practice is
particularly essential during periods of peak tick activity
(i.e., late spring and summer) but should be observed,
regardless of the season. Protective clothing, including a
hat, long-sleeved shirts, pants, socks, and closed-toe shoes
are helpful in preventing ticks from reaching the skin and
attaching. Wearing light-colored clothing is preferred
because crawling ticks can be seen easily.
Various over-the-counter products containing DEET
(N,N-diethyl-m-toluamide) are available for application on
exposed skin and clothing to repel ticks. The higher the
concentration of DEET, the longer the duration of protec-
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The following is a summary of salient features of prevention:
• Avoid tick bites, which is key to the prevention of
TBRD.
• Limit exposure to tick habitats, including grassy and
wooded areas.
• Inspect the body carefully for ticks after being in a tick
habitat.
• Remove attached ticks immediately by grasping with
tweezers close to skin and pulling gently with steady
pressure.
TBRD Cases
The following TBRD cases were observed in health-care set-
tings. Information from the cases can be used to reinforce
medical management information related to TBRD (3,22,102)
and are intended to illustrate certain common pitfalls in the
diagnosis and treatment of TBRD. The case reports include a
description of the case and salient features that can be consid-
ered when dealing with a potential case of TBRD.
Case 1
In June 2001, a girl aged 5 years was taken to an ED in
Missouri with a 3-day history of intermittent fever, head-
ache, mild nausea, and a sore throat. On physical examina-
tion, the patient had a fever of 105°F (40.6ºC) and a
maculopapular rash on her legs, including the soles of her
feet.
• What should be included in the differential diagnosis?
Possible causes of fever and rash in this child
include meningococcemia, RMSF, HME, enteroviral
infections, Kawasaki disease, drug reactions, and strep-
tococcal disease with exanthem.
• What additional information would assist with the
diagnosis?
Determine how long the rash has been present and
when and where it appeared relative to onset of fever.
The parent should be queried concerning medication
use, immunocompromising conditions, and recent
activities that could have led to animal exposures
(including dogs), sick contacts, recent travel, outdoor
activities (e.g., hiking, camping, and playing in brushy
areas or backyard), and real or potential tick exposures.
The parent noticed the rash, which began on the
arms and legs, on the same day that the child was taken
to the ED. They did not own a dog, and no history of
recent travel out of the local area and no history of a
tick bite were noted, although the parent said that ticks
were in the area around their house.
• What laboratory tests might be useful?
A CBC, comprehensive metabolic panel, blood cul-
ture, and a rapid Streptococcus pharyngitis screen should
be performed. An acute serum should be obtained for
IgG and IgM antibodies to R. rickettsii, E. chaffeensis,
and A. phagocytophilum, but subsequent management
of the patient should not depend on results. PCR for
E. chaffeensis and A. phagocytophilum using EDTA whole
blood might be useful if these tests are available from a
reference laboratory.
Laboratory results included a WBC count of 8,800 x
109 cells/L (normal: 4.5–11.0 x 109 cells/L), with 5%
bands (normal: 0%–5%), 70% neutrophils (normal:
45%–75%), 17% lymphocytes (normal: 16%–46%),
and 8% monocytes (normal: 4%–11%). The platelet
count was 50 x 109 cells/L (normal: 150–350 x 109
cells/L). Serology results were not available for 3 days.
• How does this information assist with the diagnosis?
The time of year for these clinical signs should raise
suspicion for TBRD. A normal WBC is frequently
observed in patients with viral infections and with
RMSF. Patients with RMSF will commonly develop
moderate to severe thrombocytopenia as the disease
progresses, although a normal platelet count is fre-
quently observed early in the course of illness. If sero-
logic results are not immediately available, the clinician
should not be dissuaded from initiating therapy if it is
clinically indicated.
• What actions, including treatment, should be taken?
On the basis of history, clinical signs, geographic
location, and time of year, suspicion of a TBRD is rea-
sonable. An appropriate course of action would include
treatment with doxycycline (2.2 mg/kg body weight
administered orally twice daily for a minimum of
5 days) and close follow-up to ascertain clinical response
to therapy while continuing to rule out other possible
causes. Appropriate antimicrobial therapy for other
suspected etiologies should be considered until they
can be reasonably excluded. For example, certain
experts recommend administering an intramuscular
dose of ceftriaxone, pending blood culture results,
because meningococcal disease cannot be reliably dis-
tinguished from TBRD on clinical grounds alone. Con-
valescent-phase serology for RMSF, HGA, and HME
should be performed 2–4 weeks later to confirm the
diagnosis.
• What preventive measures can the patient and her
family take to prevent infection in the future?
The most effective preventive measure is to 1) limit
exposure to ticks during peak periods of activity (prima-
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rily April–September), 2) inspect body and clothing
thoroughly for ticks after being in wooded or grassy areas,
3) remove attached ticks immediately by grasping with twee-
zers or forceps close to the skin and pulling gently with
steady pressure, and 4) apply insect repellant (e.g., DEET)
when exposure to grassy or wooded areas is anticipated.
Case 1 synopsis. This patient’s clinical history suggested
exposure to ticks, although no definitive indication of a
tick bite was reported. Ticks are small (particularly in their
nymphal and larval stages), and bites frequently go unno-
ticed because ticks might attach in places that are difficult
to observe (e.g., the scalp, axillae, and inguinal regions).
Up to 40% of patients with RMSF report no history of a
tick bite (10,11). Therefore, the clinician should not be
dissuaded from making a diagnosis of RMSF when no
report of a tick bite is made. The clinical signs and labora-
tory values and a history that are compatible with tick
exposure should guide the diagnosis and therapeutic actions.
Serum samples collected on days 7 and 35 of illness dem-
onstrated rising IgG antibody titers to R. rickettsii at 32
and 2,048, respectively.
Case 2
In mid-August 2003, a male child aged 14 months was
taken to a community health clinic in Arizona after 1 day of
fever 103.7°F (39.8°C). On physical examination, the child
had a maculopapular rash that involved his palms and soles.
On auscultation, abnormal breath sounds were detected in
the right lower lung. The parent stated that they had not
traveled out of the local area recently. No one else in the
family was ill, and the child was up-to-date on vaccinations.
Chest radiographic evaluation revealed a possible right lower
lobe infiltrate. On the basis of clinical and radiographic find-
ings, pneumonia and roseola infantum were diagnosed. The
child was administered an intramuscular injection of
ceftriaxone and sent home with a prescription for oral
amoxicillin/clavulanate.
The next day, the child was taken back to the clinic with
vomiting and rash that was petechial. His fever was 105.7°F
(41°C). He was admitted to the hospital, and antibiotic
treatment for pneumonia was continued. On day 3 of hos-
pitalization, the child developed DIC. Remarkable labora-
tory findings included: WBC count, 16.2 x 109 cells/L
(normal: 4.5–11.0 x 109 cells/L); platelet count, 46 x 109
platelets/L (normal: 150–350 x 109 cells/L); aspartate ami-
notransferase (AST), 291 U/L (normal: 10–40 U/L); and
alanine aminotransferase (ALT), 99 U/L (normal: 10–55
U/L). The child’s condition worsened, and 7 days after the
onset of illness, he died of pulmonary hemorrhage.
Case 2 synopsis. A serum sample collected 5 days before
the child’s death tested negative by IFA for IgM and IgG
antibodies reactive with R. rickettsii. However, R. rickettsii
DNA was detected in serum by PCR assay. RMSF can have
a rapid course; 50% of RMSF deaths occur within 9 days of
illness onset (10,11). IgM and IgG antibodies are typi-
cally not detectable before the second week of illness; there-
fore, serology will be not useful in diagnosing the infection
in its earliest stages. Fever and rash in a young child can be
caused by various enteroviruses, human herpesvirus 6,
N. meningitidis, measles virus, R. rickettsii, and E. chaffeensis,
among other agents. Common causes of bacterial pneumo-
nia in a child this age might include Streptococcus pneumoniae,
Staphylococcus aureus, Streptococcus pyogenes, and, less com-
monly, M. pneumoniae. Although this child lived in an area
where RMSF is not common (e.g., Arizona), the diagnosis
should not be excluded because of geography. Although
RMSF is more common in the south central and south
Atlantic states, it should be considered endemic through-
out the contiguous United States (10). TBRD are seldom
treated with the appropriate antibiotic, unless they are sus-
pected. In this context, the majority of broad spectrum
antimicrobials, including penicillins, cephalosporins,
aminoglycosides, erythromycin, and sulfa-containing drugs
are not effective against rickettsiae, ehrlichiae, or anaplasmae.
Case 3
In early June 1996, a man aged 52 years who was HIV-
seropositive sought medical care at a hospital in Florida. He had
a 4-day history of fever, headache, myalgias, nausea, and vomit-
ing. The patient had been previously healthy, with no known
previous opportunistic infections. An absolute CD4+ lympho-
cyte count of 164 cells/µl was documented 2 months before
this visit. Physical examination revealed an acutely ill man; the
patient had a fever of 103.5ºF (39.7ºC) and experienced dizzi-
ness and low blood pressure when he stood up (orthostatic
hypotension). He reported that 2 weeks before admission, he
had been bitten by a tick while hiking in central Georgia.
A CBC and chemistry panel and, because of the history
of a tick bite, serologic tests for E. chaffeensis were
ordered. Remarkable laboratory findings included hemo-
globin 11.5 g/dL (normal: 13–18 g/dL); WBC count,
2.0 x 109 cells/L (normal: 4.5–11.0 x 109 cells/L), with
66% neutrophils (normal: 45%–75%), 18% bands (nor-
mal: 0%–5%), 8% lymphocytes (normal: 16%–46%), and
8% monocytes (normal: 4%–11%); and platelet count,
16 x 109 cells/L (normal: 150–350 x 109 cells/L). Peripheral
blood smears revealed ehrlichial morulae in 2.5% of all leu-
kocytes, including monocytes, lymphocytes, atypical
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lymphocytes, neutrophils, and metamyelocytes. ALT was
73 U/L (normal: 10–55 U/L), and AST was 358 U/L
(normal: 10–40 U/L).
On the basis of laboratory and clinical findings, a diag-
nosis of HME was made, and intravenous doxycycline (100
mg every 12 hours) was initiated. Despite doxycycline
therapy, the patient remained febrile, severely thrombocy-
topenic, and continued to have elevated liver enzymes. He
developed right lower lobe pneumonia and renal failure
and died 6 days after hospitalization.
Case 3 synopsis. Patient sera obtained on days 1 and 5 of
hospitalization were negative for IgG and IgM antibodies
reactive with E. chaffeensis. However, the correct diagnosis
was revealed on admission by a finding of morulae in leuko-
cytes, and this diagnosis was subsequently confirmed when
E. chaffeensis DNA was detected by using PCR in whole
blood specimens from the patient, and the agent was iso-
lated in cell culture. HME can be a severe disease, particu-
larly in immunosuppressed persons. HME does not
commonly cause rash in adults; therefore, history of tick
exposure and characteristic leukopenia and thrombocytope-
nia were most useful in arriving at a diagnosis. Although morulae
were observed in the patient’s peripheral blood, microscopy
is generally insensitive, and morulae are reported to be
observed in only 1%–20% of patients with HME (45,47).
Therefore, a diagnosis of HME would need to be confirmed
by PCR, serology, or immunostaining, or culture isolation.
Case 4
In mid-May 1999, a female aged 69 years went to her
physician in upstate New York. She had a 3-day history of
nausea, vomiting, fatigue, and fever. She said that her dog
had died 2 days earlier after a brief illness characterized by
signs similar to her own. Physical examination revealed no
abnormalities. Her temperature was 100.4ºF (38ºC).
• What should be included in the differential diagnosis?
Possible diagnoses that should be considered include
viral syndrome, foodborne illness, and urinary tract infection.
• What additional information would assist with the
diagnosis?
Patient should be queried regarding other signs and
symptoms, recent activities and travel, exposure to other
ill persons, foods consumed, and contact with ticks.
The patient had no other symptoms to report and
reported no unusual activities or recent travel.
• What diagnostic tests, if any, are needed?
Because the patient’s symptoms were nonspecific, a
CBC should be ordered. Results will not be available
until the next day.
On the basis of the signs present when the patient
first went to her physician, she was diagnosed with gas-
troenteritis and instructed to return within 24–48
hours, if her symptoms did not improve. The patient
would be contacted regarding her laboratory test results.
The next day, the patient returned with continued
fever and changes in mental status. Her temperature
remained at 100.4ºF (38ºC), but she was notably con-
fused and lethargic. Her physical examination was
unremarkable and did not reveal the presence of a rash.
Laboratory tests obtained on the previous day
revealed a WBC count of 3.8 x 109 cells/L (normal: 4.5–
11.0 x 109 cells/L); a platelet count of 99 x 109 cells/L
(normal: 150–350 x 109 cells/L); and a hemoglobin
concentration of 12.7 g/dL (normal: 12–16 g/dL).
• How does this information assist with the diagnosis?
On the basis of the patient’s thrombocytopenia, leu-
kopenia, and worsening clinical condition, encephali-
tis and sepsis should be included in the differential
diagnosis.
• What actions, including treatment, should be taken?
On the basis of presenting signs and laboratory tests,
the patient was hospitalized and intravenous
levofloxacin therapy was initiated for fever of unknown
cause. Blood, urine, and stool cultures were ordered as
well as serologic assays for B. burgdorferi, E. chaffeensis,
and A. phagocytophilum, and PCR for E. chaffeensis and
A. phagocytophilum.
The patient’s temperature returned to normal within
48 hours, her nausea and vomiting resolved, and her
blood counts returned to normal. She was discharged
after 3 days. Blood, urine, and stool cultures revealed
no specific pathogens, and serologic assays were nega-
tive for antibodies reactive with B. burgdorferi,
E. chaffeensis, and A. phagocytophilum.
Case 4 synopsis. IHC staining of tissues from the patient’s
dog, submitted by the veterinarian to CDC, demonstrated
abundant spotted fever group rickettsial antigens, and rick-
ettsiae were identified within and around blood vessels in
multiple tissues, including brain and testes. The cause of
the dog’s illness was identified as RMSF. This information
was communicated to the patient’s physician. When the phy-
sician contacted the patient, she reported that her fatigue
and headache had persisted after discharge from the hospi-
tal. The patient was treated with oral doxycycline, and all
symptoms resolved within 1 week. Subsequent testing of the
patient’s sera for early and late convalescent-phase antibody
titer confirmed a diagnosis of RMSF. Titers of IgM and IgG
antibodies were 1,024 and 512, respectively, on day 17 and
declined to 256 and 256, respectively, on day 89 after ill-
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ness onset. The patient did not recall a tick bite and had not
seen or removed ticks from her dog, although her dog roamed
freely in wooded areas before its illness. Dogs can serve as sen-
tinels for RMSF in human populations, and infections in
canines have been associated with increased risk for infection
in their owners (22).
Case 5
In May 2001, a man aged 38 years sought medical
attention in Tennessee with complaints of headache, fever,
sore throat, and vomiting. He was treated 3 days previ-
ously by his primary care physician who diagnosed pneu-
monia and prescribed azithromycin and levofloxacin, but
his fevers persisted. He was taken to the ED by his wife,
and she said that he had new onset of confusion. He had
no pets or animal exposures. He worked as a construction
manager and was frequently outdoors in wooded areas but
did not recall a tick bite.
• What should be included in the differential diagnosis?
The initial signs and symptoms were nonspecific,
but the patient’s confused state raised concern for pos-
sible involvement of the CNS. During the summer
months, the differential diagnosis included viral men-
ingitis (particularly enteroviral), arboviral meningoen-
cephalitis (West Nile virus and others), TTP, and
TBRD. Bacterial meningitis and herpes simplex virus
(HSV) encephalitis do not have confined seasonality
but also could cause this presentation. Sepsis and other
multisystem illnesses are associated with encephalopathy,
however, so the differential diagnosis remained broad.
The patient had an oral temperature of 103.4°F
(39.7ºC); blood pressure, 100/60 mmHg; and heart rate,
120 beats/minute. The skin examination revealed dif-
fuse erythema with a several scabs on the lower legs.
Examination of the abdomen revealed moderate epigas-
tric tenderness with deep palpation but no rebound ten-
derness or organomegaly. Neurologic examination was
nonfocal, except for altered mentation (i.e., Glasgow coma
score: 13).
Laboratory testing revealed the following: WBC,
11.9 x 109 cells/L (normal: 4.5–11.0 x 109 cells/L); 84%
segmented neutrophils (normal: 45%–75%); 8% band
neutrophils (normal: 0%–5%); 3% lymphocytes (nor-
mal: 16%–46%); 5% monocytes (normal: 4%–11%);
platelets, 50 x 109 cells/L (normal: 150–350 x 109 cells/L);
total bilirubin, 3.5 mg/dL (normal: 0–1.0 mg/dL); AST,
439 U/L (normal: 10–40 U/L); ALT, 471 U/L (normal:
10–55 U/L); and alkaline phosphatase, 236 U/L (normal:
45–115 U/L). Lumbar puncture revealed a WBC of 0,
RBC of 1 with normal glucose of 55 mg/dL and normal
protein of 20 mg/dL. Creatinine was elevated at 3.9 mg/dL
(normal: 0.6–1.5 mg/dL). Computed tomography scan
of the head did not demonstrate an acute abnormality.
• How does the physical examination and laboratory
information change the differential diagnosis?
Because of the normal lumbar puncture, meningitis (i.e.,
viral or bacterial) was a less likely diagnosis. However,
examination of the CSF might be unremarkable in patients
with encephalitis. The presence of thrombocytopenia and
elevated transaminases was suggestive of TBRD. Additional
considerations included acute cholecystitis, sepsis (possi-
bly associated with DIC), toxic-shock syndrome (rash with
multiple organ failure), and TTP (i.e., acute renal failure
with fever, altered mental status, and thrombocytopenia).
• What additional tests should be performed?
Appropriate diagnostic studies should include blood
culture, serologic testing for RMSF and HME (and
PCR for these if available), prothrombin time and par-
tial thromboplastin time, examination of the periph-
eral blood smear (with particular attention for
schistocytes or intracellular morulae), and ultrasound
of the gallbladder to evaluate for inflammation.
The coagulation studies were within normal limits,
and no schistocytes or morulae were observed on
smear. Abdominal ultrasound revealed a normal gallblad-
der but mild splenomegaly. Therapy was initiated with
ceftriaxone and vancomycin. Approximately 6 hours later,
the patient developed seizures, and acyclovir and doxy-
cycline were added to the course of medicine to effec-
tively treat herpesvirus infection and TBRD. A magnetic
resonance imaging scan of the brain was normal, and
electroencephalography revealed nonspecific slowing.
Antibodies to R. rickettsii and E. chaffeensis were not
detected in acute sera. HSV PCR on CSF was negative.
Blood cultures did not grow bacteria. The patient
defervesced, and mental status normalized over the next
3 days.
Case 5 synopsis. Serum obtained 31 days after the ini-
tial signs and symptoms contained no antibodies to
R. rickettsii but had an IgG titer of 256 to E. chaffeensis,
retrospectively confirming the diagnosis of HME. Whereas
headache is a nearly universal complaint among patients
with HME, altered sensorium might be observed in up to
20% of cases (6). Other CNS manifestations include sei-
zures, meningismus, cranial nerve palsies, focal weakness,
and coma. A lymphocytic pleocytosis can be observed in
the CSF in approximately 50% of patients with HME who
undergo lumbar puncture (103). Neutrophilic pleocytosis
can be observed early in the course of the illness.
24 MMWR March 31, 2006
Neuroimaging studies are usually normal or nonspecific.
TBRD should be included in the differential diagnosis of
patients presenting with clinical evidence of CNS infec-
tion or CSF findings suggestive of aseptic meningitis.
Case 6
In July 1994, a man aged 44 years went to see his physi-
cian in central Minnesota. He complained of a 1-week
history of fever, chills, generalized myalgias, and right tem-
poromandibular joint pain. When he became ill, he treated
himself empirically with ampicillin, which was available at
home, for 2 days. Because the patient experienced no clini-
cal improvement, he sought medical care. The patient
worked outdoors and was frequently in wooded areas. Four-
teen days before he went to his physician, he removed two
deer ticks that had been attached to his skin for an
unknown period.
Physical examination findings. The patient had a low-
grade fever of 100.6ºF (38.1ºC). Examination of heart,
lungs, and abdomen were normal. No lymphadenopathy,
hepatosplenomegaly, or skin rash were noted. Cardiovas-
cular, pulmonary, gastrointestinal, or neurological symp-
toms were not present. Overall, physical examination was
unremarkable, except for fever.
Laboratory findings. No laboratory evaluations were per-
formed during the visit. A presumptive diagnosis of acute
Lyme disease was made, and empirical treatment with
amoxicillin and probenecid was initiated; a 1-week follow-
up visit was scheduled. Five days after the outpatient visit,
the patient died suddenly at home. He had complained of
shortness of breath the day before his death.
Case 6 synopsis. Histopathologic examination of the
patient’s heart revealed widespread transmural myocardi-
tis with neutrophilic and lymphocytic infiltrates. Postmor-
tem serum specimens were evaluated initially for
presumptive carditis as a result of B. burgdorferi infection.
Serum titers of IgG and IgM antibodies to B. burgdorferi
were not detected by ELISA and western blotting. PCR
assays of serum and whole blood for B. burgdorferi also were
negative. However, antibody titers to A. phagocytophilum
(formerly known as E. equi) were significantly elevated at
titer >256 by IFA methods. Detection of DNA extracted
by PCR from whole blood and positive IHC staining of
cardiac tissue confirmed a diagnosis of anaplasmosis.
Although infection with A. phagocytophilum was demon-
strated in this case, the pathogenesis of the associated carditis
was less clear (104).
The diagnosis of HGA can be difficult because of the
nonspecific nature of the febrile illness frequently observed
when the patient first seeks medical care. In regions where
both Lyme disease and HGA are known to occur, distin-
guishing between the diseases in the early stages of illness
might be difficult. Because treatment should be initiated
before a definitive diagnosis is made, selection of an anti-
microbial effective against both rickettsial organisms and
B. burgdorferi (e.g., doxycycline) is recommended. This case
also underscores the importance of close follow-up of
patients treated for TBRD on an outpatient basis. Because
these diseases can rapidly progress, clinicians should
emphasize to patients the need to return for reevaluation if
substantial improvement is not observed within 24–48
hours of initiation of treatment.
Conclusion
TBRD continue to cause severe illness and death in oth-
erwise healthy adults and children, despite the availability
of low cost, effective antimicrobial therapy. The greatest
challenge to clinicians is the difficult diagnostic dilemma
posed by these infections early in their clinical course when
antibiotic therapy is most effective.
Early clinical presentations of HME, HGA, RMSF, and
E. ewingii infection include fever, headache, myalgia, and
malaise and are difficult to distinguish from other infectious
and noninfectious diseases. Rash is observed frequently in
RMSF, occasionally in HME, and rarely in HGA. TBRD
tend to occur seasonally, with the majority of cases occurring
during the warmer spring and summer months. However,
cases might develop year-round. A detailed history of recent
recreational or occupational activities might reveal potential
exposure to ticks, although the absence of a history of a
recent tick bite should not dissuade clinicians from consid-
ering a diagnosis of TBRD.
TBRD can be life-threatening. Severe manifestations of
TBRD include prolonged fever, renal failure, myocarditis, men-
ingoencephalitis, hypotension, acute respiratory distress syn-
drome, and multiple organ failure. Patients usually do not
have diagnostic serum antibody levels during the first week of
illness; therefore, an inability to detect antibodies (IgG or IgM)
in acute-phase serum does not exclude TBRD. Health-care
providers should not delay treatment while waiting for a diag-
nosis; rather, they should empirically provide treatment if they
suspect TBRD. Doxycycline is the drug of choice for the treat-
ment of presumptive or confirmed TBRD in both adults and
children.
Examination of paired serum samples obtained during
acute illness and 2–3 weeks later that demonstrate a rise in
antibody titer is the most appropriate approach to confirm
TBRD. Physicians who identify a potential case of TBRD
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should notify the local health department, which can assist
with obtaining diagnostic testing to confirm the diagnosis.
No licensed vaccines for TBRD are available. Avoiding
tick bites and promptly removing attached ticks remain
the best disease prevention strategies.
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Goal and Objectives
This report provides practical information on the diagnosis, treatment, and reporting of tickborne rickettsial diseases (TBRD). This report represents a collaborative
effort by a work group comprised of general practitioners, adult and pediatric infectious disease specialists, clinical laboratorians, and epidemiologists from clinical
practice, academic centers, and CDC. The goal of this report is to present a framework to assist clinicians in recognizing the symptoms of TBRD, obtaining
appropriate diagnostic tests, and initiating prompt and effective treatment. Upon completion of this educational activity, the reader should be able to 1) describe
common epidemiologic manifestations of TBRD; 2) describe common clinical manifestations of TBRD; 3) list a differential diagnosis that ranks TBRD; 4) identify
treatment decisions based on epidemiologic clues; 5) identify treatment decisions based on clinical clues; 6) identify the utility of confirmatory laboratory assay for
TBRD; and 7) identify doxcycline treatment for patients with suspected TBRD.
To receive continuing education credit, please answer all of the following questions.
8. Serologic tests are requested on a patient with onset of febrile illness
and maculopapular rash 3 days ago. Serum IgG and IgM antibodies to
R. rickettsii are negative. What can you conclude concerning the
etiology of the patient’s condition?
A. The absence of antibodies indicates that the person does not have RMSF.
B. Antibodies might not be present during the first week of illness;
absence of antibodies does not rule out RMSF.
C. Tests for other TBRD should be ordered because rash is more
commonly observed with human monocytotropic (or monocytic)
ehrlichiosis (HME) or human granulocytotropic (or granulocytic)
anaplasmosis than with RMSF.
9. When considering a diagnosis of TBRD, important questions to
identify during the patient interview include...(Indicate all that apply.)
A. recent history of crawling or attached tick on person.
B. recent history of crawling or attached ticks on pet animals (i.e., dogs).
C. recent history of outdoor recreational activity (e.g., camping, hiking, or
walking a dog).
D. recent foreign or domestic travel to a TBRD-endemic region.
E. all of the above.
10. Which of the following laboratory results meet the case definition of
a confirmed case of HME? (Indicate all that apply.)
A. Demonstration of 4-fold change in antibody titer against E. chaffeensis.
B. Single positive antibody titer against E. chaffeensis.
C. Detection of E. chaffeensis DNA in a clinical specimen by using
polymerase chain reaction assay.
D. Identification of morulae in leukocytes.
E. A and C only.
11. Which best describes your professional activities?
A. Physician.
B. Nurse.
C. Health educator.
D. Office staff.
E. Other.
12. I plan to use these recommendations as the basis for…(Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
13. Overall, the length of the journal report was…
A. much too long.
B. a little too long.
C. just right.
D. a little too short.
E. much too short.
14. After reading this report, I am confident I can describe common
epidemiologic manifestations of TBRD.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
1. During the first 4–5 days of one or more of TBRD, which of the
following signs or laboratory results could be reasonably expected?
A. Presence of maculopapular rash.
B. Evidence of leukopenia or thrombocytopenia.
C. Demonstration of serum antibodies against one of the agents of TBRD.
D. All of the above.
E. A and B only.
2. Which etiologic agent(s) of TBRD can be occasionally observed on
peripheral blood smears by using routine stains?
A. Rickettsia rickettsii.
B. Ehrlichia chaffeensis.
C. Anaplasma phagocytophilum.
D. All of the above.
E. B and C only.
3. Concerning the epidemiology of TBRD...(Indicate all that apply.)
A. clustering of cases within families or communities is well-described.
B. the majority of cases occur during April–September.
C. Rocky Mountain spotted fever (RMSF) is endemic throughout the
majority of the United States.
D. all of the above.
E. A and B only.
4. Concerning the rash of RMSF…(Indicate all that apply.)
A. it typically begins as pink macules.
B. it generally appears on the same day as onset of fever.
C. it generally appears 2–4 days after onset of illness.
D. A and C only.
E. A and B only.
5. Treatment of TBRD using doxycycline should only be initiated after
laboratory confirmation of infection is obtained.
A. True.
B. False.
6. Which of the following antimicrobial agents is the drug of choice for
a child aged 4 years with suspected RMSF?
A. Chloramphenicol.
B. Trimethoprim-sulfamethoxazole.
C. Doxycycline.
D. Amoxicillin/clavulanate.
7. Which of the following are considered appropriate for tick removal?
(Indicate all that apply.)
A. Kerosene.
B. Fingernail polish.
C. Lit matches.
D. Fine-tipped forceps.
E. All of the above.
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15. After reading this report, I am confident I can describe common
clinical manifestations of TBRD.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can list a differential
diagnosis that ranks TBRD.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can identify treatment
decisions based on epidemiologic clues.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can identify treatment
decisions based on clinical clues.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
19. After reading this report, I am confident I can identify the utility of
confirmatory laboratory assay for TBRD.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
20. After reading this report, I am confident I can identify doxcycline
treatment for patients with suspected TBRD.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
21. The learning outcomes (objectives) were relevant to the goals of this
report.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
22. The instructional strategies used in this report (text, figures, tables,
box, and appendix) helped me learn the material.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–10.
1. E; 2. E; 3. D; 4. D; 5. B; 6. C; 7. D; 8. B; 9. E; 10. E.
23. The content was appropriate given the stated objectives of the report.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
24. The content expert(s) demonstrated expertise in the subject matter.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
25. Overall, the quality of the journal report was excellent.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
26. These recommendations will improve the quality of my practice.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
27. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
28. The MMWR format was conducive to learning this content.
A. Strongly agree.
B. Agree.
C. Undecided.
D. Disagree.
E. Strongly disagree.
29. Do you feel this course was commercially biased? (Indicate yes or no;
if yes, please explain in the space provided.)
A. Yes.
B. No.
30. How did you learn about the continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR subscription.
F. Other.
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